Using gene and microRNA expression in the human airway for lung cancer diagnosis by Gerrein, Joseph
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Using gene and microRNA
expression in the human airway for
lung cancer diagnosis
https://hdl.handle.net/2144/14145
Boston University
BOSTON UNIVERSITY 
GRADUATE SCHOOL OF ARTS AND SCIENCES 
AND 
COLLEGE OF ENGINEERING 
 
Dissertation 
 
USING GENE AND microRNA EXPRESSION IN THE HUMAN AIRWAY  
FOR LUNG CANCER DIAGNOSIS 
 
by 
 
JOSEPH GERREIN 
B.S., Columbia University, 2005 
 
 
 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
2014 
  
Approved by 
 
 
 
 
 
 
First Reader  ________________________________________________ 
Avrum Spira, MD, MSc 
Professor of Medicine, Pathology & Laboratory Medicine, 
and Bioinformatics 
 
 
 
Second Reader  ________________________________________________ 
Mark Kon, Ph.D. 
Professor of Mathematics and Statistics 
 
 
 
 
iii 
Acknowledgements 
I would like to thank my family and friends who have given me love and support.  
I would especially like to thank my beautiful wife, Rachel, and Mom, Dad, and 
Emily.  Additional thanks go to Dave Hill, Adam Gower, Armen, and Ed. 
 
Thank you, Avi for always believing in me and supporting me, especially when I 
needed expensive ergonomic and voice-recognition equipment so that I could do 
my work.  Thank you, Christina for being a wonderful collaborator and friend.  I 
would also like to thank Marc Lenburg and Mark Kon for making time to meet 
with me and for all of the great computational and general advice they have given 
me.  I am also very grateful to Josh and Catalina for their friendship. 
 
There are many other people in the Spira-Lenburg lab, BU Bioinformatics 
program, Abundant Grace Church, and elsewhere that I do not have time to 
thank individually.  All of you have been a blessing to me.
iv 
USING GENE AND microRNA EXPRESSION IN THE HUMAN AIRWAY  
FOR LUNG CANCER DIAGNOSIS 
(Order No.        ) 
JOSEPH GERREIN 
Boston University Graduate School of Arts and Sciences  
and 
College of Engineering, 2014 
Major Professor: Avrum Spira, Professor of Medicine 
 
ABSTRACT 
 
Lung cancer surpasses all other causes of cancer-related deaths 
worldwide.  Gene-expression microarrays have shown that differences in the 
cytologically normal bronchial airway can distinguish between patients with and 
without lung cancer.  In research reported here, we have used microRNA 
expression in bronchial epithelium and gene expression in nasal epithelium to 
advance biological understanding of the lung-cancer “field of injury” and develop 
new biomarkers for lung cancer diagnosis. 
MicroRNAs are known to mediate the airway response to tobacco smoke 
exposure but their role in the lung-cancer-associated field of injury was 
previously unknown.  Microarrays can measure microRNA expression; however, 
they are probe-based and limited to detecting annotated microRNAs.  MicroRNA 
sequencing, on the other hand, allows the identification of novel microRNAs that 
may play important biological roles.  We have used microRNA sequencing to 
v 
discover novel microRNAs in the bronchial epithelium.  One of the predicted 
microRNAs, now known as miR-4423, is associated with lung cancer and airway 
development.  This finding demonstrates for the first time a microRNA expression 
change associated with the lung-cancer field of injury and microRNA mediation of 
gene expression changes within that field. 
The National Lung Screening Trial showed that screening high-risk 
smokers using CT scans decreases lung-cancer-associated mortality.  Nodules 
were detected in over 20% of participants; however, the overwhelming majority of 
screening-detected nodules were non-malignant.  We therefore need biomarkers 
to determine which screening-detected nodules are benign and do not require 
further invasive testing.  Given that the lung-cancer-associated field of injury 
extends to the bronchial epithelium, our group hypothesized that the field of injury 
may extend farther up in the airway.  Using gene expression microarrays, we 
have identified a nasal epithelium gene-expression signature associated with 
lung cancer.  Using samples from the bronchial epithelium and the nasal 
epithelium, we have established that there is a common lung-cancer-associated 
gene-expression signature throughout the airway.  In addition, we have 
developed a nasal epithelium gene-expression biomarker for lung cancer 
together with a clinico-genomic classifier that includes both clinical factors and 
gene expression.  Our data suggests that gene expression profiling in nasal 
epithelium might serve as a non-invasive approach for lung cancer diagnosis and 
screening.
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1. General Introduction 
 
1.1 Lung Cancer 
 
Lung cancer surpasses all other causes of cancer-related deaths in the United 
States and worldwide.  In the United States, an estimated 157,300 people died 
from lung cancer in 2010, compared to 40,230 from breast cancer (Jemal et al., 
2010).  Lung cancer is typically diagnosed after it has progressed to an advanced 
stage and the most recent statistic for 5-year survival rate is 17.3% (Howlader N, 
2013).  The low survival rate is due in part to the lack of effective, minimally 
invasive diagnostic and screening tools.  Lung cancer typically occurs in 
smokers, with approximately 85% of lung cancer patients being current or former 
smokers.  However, only 10% of smokers are diagnosed with lung cancer over 
their lifetime.  Given this, lung cancer risk is multifactorial and smoking itself is 
not a strong predictor of lung cancer development.  Key to predicting lung cancer 
development may be measuring an individual’s physiological response to smoke 
exposure, which can be done with molecular biomarkers in the airway. 
 
1.2 Current Tools for Lung Cancer Diagnosis and Screening 
 
Given that early stage lung cancer does not produce symptoms, or only produces 
symptoms that are not specific for lung cancer (e.g. shortness of breath, 
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hemoptysis, and weight loss), an effective lung cancer screening tool is needed.  
Currently, no lung cancer screening tool is used in common practice in the United 
States.  In a new screening study, the National Lung Screening Trial (NLST) 
(Aberle et al., 2011) showed a decrease in lung cancer mortality through 
screening 53,454 participants who were at high risk for lung cancer based on 
three criteria: cumulative tobacco exposure from active smoking ( > 30 pack 
years, e.g. at least one pack a day for 30 years or two packs a day for 15 years), 
age (55 to 74 years), and status as a current or former smoker (former smokers 
must have quit more recently than 15 years ago).  The NLST compared 3-year 
screening by annual low-dose helical CT to screening by chest x-rays and found 
that the low-dose helical CT method decreased lung cancer mortality by 20% as 
compared to the chest x-ray method (lung cancer mortality of 247 per 100,000 
person-years for CT and 309 per 100,000 person-years for x-ray).  However, the 
false positive rate was extremely high (96%) and abnormalities were detected by 
CT in over 20% of subjects.  Subjects with radiographic abnormalities were 
subjected to a clinical workup that included invasive diagnostic procedures.  
Given the high false positive rate, CT alone is not an ideal screening tool. 
 
The standard initial tests for establishing lung cancer diagnosis in current and 
former smokers, namely radiographic chest scans and bronchoscopy, are not 
highly effective.  Although bronchoscopy is sensitive in the case of an 
endobronchial tumor that can be sampled readily via the airway, it lacks 
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sensitivity for small masses and masses that are peripherally located in the lung.  
While bronchoscopy is less invasive than needle biopsy and lung resection, it is 
not a noninvasive procedure.  Before the procedure begins, the patient must be 
cannulated (insertion of a tube into a vein in order to deliver medication) and 
given anesthetic.  During the procedure, trauma is caused by tissue biopsy and 
by the bronchoscope hitting against the airway walls. 
 
With regards to CT scanning, radiographically detected abnormalities are 
nonspecific, and differentiating a tumor from a nonmalignant mass or alternative 
diagnosis such as pneumonia is not possible.  As a result, more invasive tests 
are required to follow up on radiographic abnormalities that typically turn out to 
be noncancerous.  In addition to being subjected to invasive tests, patients suffer 
emotionally after they are notified of being under clinical suspicion for lung 
cancer.   Despite the use of modern procedures for lung cancer diagnosis, false 
positives occur and a significant percentage of patients are sent for lung 
resection even when they do not have lung cancer. 
 
1.3 Emerging Tools for Minimally Invasive Lung Cancer Diagnosis and 
Screening 
 
A number of authors have shown, at least in small cohorts, the ability to diagnose 
lung cancer using molecular tests on blood, sputum, saliva, or normal airway 
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epithelial cells found distal to the tumor (Brothers et al., 2013).  Collecting these 
samples is less invasive than taking biopsies, and these types of minimally 
invasive tests are badly needed to improve lung cancer screening and diagnosis.  
The biomarkers developed thus far involve molecular assays for methylation, 
gene expression, or microRNA expression but never a combination of molecular 
types.  Using these types of molecular biomarkers individually or in combination 
may produce an effective lung cancer screening tool for the first time.   
 
Some of the published molecular biomarkers described in the following survey 
were not validated in a real-world cohort.  Biomarkers for screening should be 
developed in a screening population of asymptomatic high-risk individuals and be 
validated by longitudinal follow-up.  Biomarkers for diagnosis should be validated 
in subjects under suspicion of lung cancer, which includes subjects with all types 
of malignant lung cancer (including both non-small cell lung cancer and small cell 
lung cancer) and subjects with alternative pathologies of the chest such as 
pneumonia, tuberculosis, and sarcoidosis.  A common shortcoming of published 
diagnostic biomarkers is that the control group is composed of healthy 
individuals.  There are a number of molecular differences simply between healthy 
and sick individuals that are nonspecific to lung cancer but may be learned by a 
classifier and used to discriminate between the cancer and control groups.  
Therefore, positive results from diagnostic studies comparing cancer subjects to 
healthy controls may be misleading.  
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A promising type of sample used for minimally invasive molecular biomarker 
development is sputum, which originates from deep in the lung and contains 
bronchial epithelial cells and alveolar macrophages (Thunnissen, 2003).  Sputum 
from patients with lung cancer may in fact contain cancer cells that can be 
identified using cytopathology, although this method has low sensitivity.  
Centrally located and advanced stage tumors are most likely to contribute cancer 
cells to sputum, and these are the easiest types of cancer to diagnose using 
other methods, e.g. bronchoscopy.  The review article by Thunnissen states that 
in addition to the presence of cancer cells, molecular changes such as K-Ras 
and P53 mutations, loss of heterozygosity, and DNA adducts are also detectable 
in sputum. 
 
Yu et al. developed a biomarker for adenocarcinoma using microRNA expression 
from a panel of microRNAs detected in sputum (Yu et al., 2010).  Similarly to the 
study design of Xing et al. (Xing et al., 2010), the authors used a three-step 
process: 1) marker discovery in paired normal and tumor samples, 2) marker 
optimization using sputum in a case-control group of cancer patients vs. healthy 
subjects, and 3) marker validation on independent test set.  The authors 
identified 7 microRNAs in tumor vs. adjacent normal and used the case-control 
group to select 4 of them to validate.  In the training set, the biomarker 
distinguished lung adenocarcinoma patients from normal subjects with 80.6% 
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sensitivity and 91.7% specificity.  Two test sets were used: one composed of 33 
subjects with adenocarcinoma (biomarker performance of 80.6% sensitivity, 
92.5% specificity) and one composed of 31 subjects with squamous cell 
carcinoma (biomarker performance of 64.1% sensitivity, 71.3% specificity).  
Averaged over both test sets, the sensitivity of the biomarker is roughly 72% and 
specificity is roughly 82%. 
 
Xing et al. developed a panel of microRNAs as a lung cancer biomarker in 
sputum (Xing et al., 2010).  Limiting the study to squamous cell carcinoma, first 
the authors identified 6 microRNAs that are differentially expressed between 15 
paired tumor and adjacent normal samples.  Second, the authors profiled these 
microRNAs, using PCR, in a case-control group of 48 cancers and 48 healthy 
controls.  Third, the authors selected three microRNAs (miR-205, miR-210 and 
miR-708) that best discriminated the cancer and control groups.  Finally, the 
authors tested their microRNA panel on an independent test set of 67 lung 
squamous cell carcinoma patients and 55 healthy subjects.  The authors report 
sensitivity and specificity on the training set as 73% and 95% respectively, but 
the performance on the test set is not clearly stated.  It is likely that the 
microarray panel performed poorly in an independent test set; however, the 
mean expression of each microRNA between the cancer group and control group 
in the test set is significantly different (p less than 0.001). 
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There have been a number of manuscripts reporting lung cancer-associated 
gene expression in normal bronchial airway epithelial cells (Beane et al., 2012; 
Gustafson et al., 2010; Spira et al., 2007b; Woenckhaus et al., 2006),.  Our group 
has shown that lung cancer can be diagnosed using bronchial epithelial cells 
obtained via brushing during bronchoscopy (Spira et al., 2007a).  The procedure 
of collecting epithelial cells via brushing fits into the current clinical workflow, as 
bronchoscopy is the standard diagnostic test for smokers under suspicion of lung 
cancer.  Spira et al. published an 80-gene biomarker that used a simple weighted 
voting classifier that achieved 80% sensitivity and 84% specificity on an 
independent test set (n = 52).  By combining the 80-gene biomarker with 
cytopathology, the authors achieved performance of 95% sensitivity and 95% 
negative predictive value.  In a follow-up study, Beane et al. showed that the 80-
gene biomarker was predictive of lung cancer independently of standard clinical 
risk factors and CT measurements, i.e. age, smoking history, radiographic mass 
size and lymphadenopathy (Beane et al., 2008).  Based on the 80-gene 
biomarker, Allegro Diagnostics Inc. has developed a product, BronchoGen™, 
which is currently being validated in a multicenter trial. 
 
Blood biomarkers for lung cancer are a major research focus.  The main 
advantages of blood biomarkers are that blood draws are relatively noninvasive 
and are already routinely taken from patients.  In addition, a blood biomarker 
could be easily validated using banked blood that is already available.  However, 
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the processing of the stored blood samples may make them unusable for some 
types of blood biomarkers that are being developed.  One type of biomarker 
currently studied in blood is microsatellites, which are short repeat sequences in 
DNA that are unstable in cancer.  Microsatellite instability has been shown in 
tumor tissue in colorectal cancer (Boland and Goel, 2010), plasma DNA of small 
cell lung cancer patients, and sputum and bronchial epithelia of lung cancer 
patients (Miozzo et al., 1996).  Another type of blood biomarker is free circulating 
DNA.  Sozzi et al. showed that free circulating DNA in plasma can be used in 
non-small cell lung cancer detection (Sozzi et al., 2001).  The authors used PCR 
amplification of the human telomerase reverse transcriptase gene (hTERT) in 
100 non-small cell lung cancer patients and 100 controls matched for smoking, 
age, and sex.  They found that the concentration of circulating DNA in cancer 
subjects was significantly higher than in control subjects.  On their training set, 
they achieved AUC of 0.94.  Based on this study, Sozzi et al. then tried using 
plasma DNA concentration for screening in a cohort of 1,035 heavy smokers 
followed over 5 years with annual CTs.  In the screening study, plasma DNA 
concentration was not different between subjects who developed CT-detected 
cancer, and cancer free control subjects (Sozzi et al., 2009). 
 
1.4 Dissertation Aims: Using Gene Expression and microRNA Expression 
for Lung Cancer Diagnosis 
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The current tools for diagnosing lung cancer are invasive and there is room for 
improvement in both sensitivity and specificity.  The focus of this dissertation is to 
develop minimally invasive, molecular diagnostics for lung cancer using gene 
and microRNA expression in the human airway. 
 
Aim 1: Discover novel microRNAs in human bronchial epithelial cells that 
may be associated with lung cancer 
It has previously been demonstrated that cigarette smoke creates a molecular 
field of injury throughout the airway (Spira et al. 2004, Sridhar et al. 2008, Zhang 
et al. 2010) and that microRNAs in bronchial epithelium are modulators of the 
smoking field of injury (Schembri, 2009).  Previous studies of microRNAs in the 
airway have used microarrays and PCR to profile microRNA expression, both of 
which are limited to detecting known microRNAs.  The newer technology of RNA-
seq enables the identification of novel microRNAs that may play important 
biological roles.  We have hypothesized that by using RNA-seq, we could identify 
novel microRNAs expressed in bronchial airway epithelium that play a role in 
lung cancer.  Our goal was to discover and characterize novel microRNAs in 
human bronchial epithelial cells.  This work is described In Chapter 2. 
 
Aim 2: Develop a minimally invasive, nasal epithelium gene expression 
biomarker for lung cancer diagnosis  
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Given that, 1) Gene-expression differences in the cytologically normal bronchial 
airway can distinguish between patients with and without lung cancer (Spira et 
al., 2007b) and 2) Smoking-induced gene expression changes in nasal 
epithelium reflects smoking-induced gene expression changes in the bronchial 
epithelium (Sridhar et al., 2008; Zhang et al., 2010), we have hypothesized that 
gene expression differences in nasal epithelium can distinguish between patients 
with and without lung cancer.  The main goal of this aim was to develop 
minimally invasive, nasal epithelium gene expression biomarkers for lung cancer 
diagnosis.  This work is described in Chapters 3, 4, and 5.  The main work is 
described in chapter 3 whereas ensemble biomarker development is described in 
chapter 4.  In the process of biomarker development, I created a biomarker 
development pipeline that is described in Chapter 5. 
11 
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2. Discovery of a Novel microRNA From RNA-Sequencing of Bronchial 
Airway Epithelial Cells 
 
2.1 Introduction 
 
MicroRNAs are regulators of gene expression that are expressed in a cell-type-
specific fashion (Landgraf et al., 2007) and play key roles in cancer and many 
other biological processes (Ambros, 2004; Garzon et al., 2009).  Normal 
bronchial epithelium is a tissue of clinical interest, as mRNA expression in this 
tissue has been used for lung cancer diagnosis (Spira et al., 2007c), but there 
has not previously been a microRNA discovery effort in bronchial epithelial cells.  
The detection and expression profiling of novel (i.e. unannotated and unreported) 
microRNAs can be accomplished using RNA sequencing, a new technology that 
has significant computational challenges (Friedlander et al., 2008).  
 
We have hypothesized that previously undiscovered microRNAs expressed in 
bronchial epithelial cells may play mechanistic roles in lung tumorigenesis or aid 
in lung cancer detection, prevention, or therapy.  The goal of this study was to 
use RNA sequencing to discover novel microRNAs in bronchial epithelial cells.  
We have discovered a novel microRNA (now known as hsa-miR-4423) and have 
shown that the human DNA sequence of hsa-miR-4423 is only conserved in 
simians, a subset of the primates.  This microRNA has been extensively 
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characterized and these findings suggest that the level of miR-4423 expression 
in the bronchial epithelium may be used as a diagnostic biomarker for lung 
cancer.  As part of the process of predicting novel microRNAs, I modified the 
original miRDeep package code to use a new alignment tool, Bowtie (Langmead 
et al., 2009) instead of MegaBLAST (McGinnis and Madden, 2004).  Bowtie is a 
superior alignment tool as it guarantees finding the best alignment (if the number 
of allowed mismatches is small) whereas MegaBLAST uses a heuristic and does 
not guarantee the best match. 
 
2.2 Background 
 
2.2.1 Motivation for Discovering Novel microRNAs in Bronchial Epithelial 
Cells 
Smoking creates a field of injury throughout the airway (Schembri et al., 2009; 
Spira et al., 2004; Sridhar et al., 2008; Zhang et al., 2010), including 
perturbations in bronchial airway microRNA expression.  In the bronchial airway 
response to cigarette smoke exposure, microRNAs modulate smoking-induced 
mRNA expression and therefore play a regulatory role in the gene expression 
response to smoke exposure (Schembri et al., 2009).  Our group has shown that 
lung cancer can be diagnosed using gene expression from normal bronchial 
epithelial cells (Spira et al., 2007c), making normal bronchial epithelial cells a 
clinically relevant tissue for molecular biomarkers.  The tools for comprehensive 
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profiling of microRNA expression have not been available until recently, and we 
have yet to explore bronchial epithelial microRNA expression in subjects with 
lung cancer.  MicroRNAs in normal bronchial epithelium of lung cancer subjects 
may be perturbed by the cancer field and modulate the gene expression 
response within the cancer field.  If microRNA expression in normal bronchial 
epithelial cells is perturbed by the cancer field, the epithelial cells may be used as 
minimally invasive diagnostic biomarkers, targets for therapy, or guides for 
chemoprevention. 
 
Traditional methods of measuring microRNA expression are PCR and 
microarrays, both of which are based on probes that are designed to hybridize to 
specific sequences based on prior knowledge of expressed transcripts.  In order 
to identify novel microRNAs, RNA sequencing has been employed, which 
enables the detection and expression profiling of novel (i.e. unannotated) 
transcripts.  Once discovered, the novel microRNAs can then be characterized.   
 
2.2.2 Overview of microRNA Biogenesis, Structure, and Function 
MicroRNAs (miRNAs) are small (~22 nucleotides long), non-coding, regulatory 
RNAs that are important in cancer and a large number of other biological 
processes (Ambros, 2004; Garzon et al., 2009).  MicroRNAs target specific 
genes based on sequence complementarity and other physical properties.  
MicroRNAs reduce gene expression by guiding silencing complexes to bind to 
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mRNA and block translation or promote mRNA degradation.  The existence of 
microRNAs was unknown until relatively recently, and understanding their 
function, biogenesis, and target specificity has been a challenging and rapidly 
evolving area of research. 
 
The following overview of microRNA biogenesis serves to give an understanding 
of microRNA biology and to mention features that are used for novel microRNA 
discovery.  The classical model of microRNA biogenesis is summarized by the 
following steps (Krol et al., 2010; Winter et al., 2009): 
1) A primary miRNA transcript (pri-miRNA) is transcribed from DNA by RNA 
polymerase II or III.  The pri-miRNA folds into a hairpin that has a 3’ arm 
and a 5’ arm. 
2) The pri-miRNA is processed in the nucleus to create a smaller (~70 
nucleotide long) precursor RNA (pre-miRNA).  The processing is 
accomplished by the microprocessor complex, a protein complex that 
includes Drosha and DGCR8. 
3) The pre-miRNA is exported from the nucleus to the cytoplasm by Exportin-
5-Ran-GTP.  In order to be recognized by Exportin-5, the pre-miRNA must 
have a double-stranded stem loop of a specific length and a 3’ overhang. 
4) Dicer and TRBP process the pre-miRNA, which has a 3’ arm and a 5’ arm, 
into a duplex containing two mature microRNAs that are each 
approximately 22 nucleotides long.  There are two nucleotides that extend 
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beyond the 3' end of each of the individual mature microRNAs in the 
duplex.  The mature microRNA derived from the 3’ arm of the hairpin is 
termed “3p” and the mature microRNA derived from the 5' arm is termed 
“5p”.  In the tradition model of microRNA biogenesis it was thought that 
only one of the two products was incorporated into the miRNA-induced 
silencing complex (miRISC; termed the “mature” microRNA, e.g. hsa-miR-
20b) and the other product was degraded (termed the “star” microRNA, 
e.g. hsa-miR-20b*).  These terms, “mature” and “star” are used in 
miRDeep terminology.  However, this biogenesis model is outdated, as it 
has been shown that many times both microRNAs from the same hairpin 
are functional (Yang et al., 2011). 
5) The microRNA duplex disassociates and either one or both of the 
products becomes a functional microRNA by being loaded into an 
Argonaute protein in the miRISC.   
6) The miRISC-incorporated mature microRNAs guide the miRISC to target 
specific mRNAs based on sequence complementarity and decrease gene 
expression by blocking mRNA translation or promoting mRNA 
deadenylation and degradation.  A recent publication has shown that 
mammalian microRNAs most commonly act by promoting mRNA 
degradation (Guo et al., 2010). 
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2.2.3 Overview of microRNA Prediction Algorithms for RNA-Seq Data 
A number of microRNA prediction algorithms have been published including 
miRDeep (Friedlander et al., 2008), miRanalyzer (Hackenberg et al., 2009),  
miRTRAP (Hendrix et al., 2010), MIReNA (Mathelier and Carbone, 2010),  
mirTools (Zhu et al., 2010), miRExpress (Wang et al., 2009), DSAP (Huang et 
al., 2010), and miRNAkey (Ronen et al., 2010).  These algorithms have different 
ways of aligning RNA-seq reads and predicting novel microRNAs, as well as 
different implementations (i.e. web server vs. local installation).  A recent paper 
compares the performance of 8 microRNA prediction algorithms across deep 
sequencing data sets from three different species: Homo sapiens, Gallus gallus, 
and Caenorhabditis elegans (Li et al., 2012).  At the time that the novel 
microRNA prediction analysis described in this chapter was performed, there 
were two published microRNA prediction algorithms for RNA-seq data: miRDeep 
(Friedlander et al., 2008) and miRanalyzer (Hackenberg et al., 2009) and both 
were used in the analysis.  I will compare and contrast these two methods below. 
 
2.2.4 miRDeep 
The miRDeep algorithm employs a probabilistic model of microRNA biogenesis 
to assign scores to potential novel microRNA precursors.  Using a Bayesian 
model, miRDeep computes a log-odds score for each potential precursor (note 
that the scores are assigned to candidate precursors as opposed to candidate 
mature microRNAs).  MiRDeep compares the probability that the pattern created 
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by alignment of RNA-seq reads aligned to a genomic location were produced by 
Dicer processing of a microRNA precursor to the probability that they were not 
produced by Dicer processing using the formula:  
score = log (P(precursor | data) / P(background | data) 
where precursor and background represent sequences that do or do not belong 
to microRNA precursors, respectively.  Using Bayes theorem,  
P(precursor | data) = P(data | precursor) P(precursor) / P(data).  
 
The terms for calculating P(precursor | data) in the miRDeep model are intuitive 
as they represent core properties of microRNA hairpins or the way that 
microRNA expression signatures are dominated by reads aligned to the mature 
microRNA regions.  These core microRNA properties used by miRDeep are: 1) 
MicroRNA precursors fold into a hairpin that has a lower free energy than other 
types of RNA (Bonnet et al., 2004); 2) T microRNA expression should be 
reflected by a large number of aligned reads in the positions of the putative 
mature microRNAs and a minimal number of reads aligning to the rest of the 
putative precursor; 3) Reads should align to both mature microRNAs in the 
hairpin; and 4) The seed regions of mature microRNAs are often shared with 
those of other known microRNAs.    
 
MiRDeep defines the probability that the potential precursor is a true microRNA 
hairpin by: 
18 
 
P(precursor | data) = P(abs | precursor) * P(rel | precursor) * P(sig | precursor) * 
P(star | precursor) * P(nuc | precursor) * P(precursor) / P(data) 
where:  
P(abs | pre) is the precursor probability based on its minimum free energy as 
calculated by RNAfold (Hofacker and Stadler, 2006), P(rel | pre) is the precursor 
probability based on energetic stability as computed by Randfold (Bonnet et al., 
2004) (Randfold is only computed in cases where the overall miRDeep score is 
borderline), P(sig | pre) is the precursor probability given the number of reads 
that aligned to the precursor in a Dicer-consistent fashion, P(nuc | pre) is the 
precursor probability based on whether the putative “mature” microRNA seed is 
shared with known microRNAs, P(star | pre) is the precursor probability that at 
least one read aligns to the putative “star” sequence, and P(pre) is the precursor 
prior probability that is set by default to 0.5. 
 
The miRDeep authors used data from C. elegans to learn the probabilities and 
applied the C. elegans-based model to C. elegans and human microRNA data.  
The same were learned from C. elegans training data used by the miRDeep 
authors as opposed to being learned from the species of interest (e.g. using 
human data to learn probabilities for human microRNA prediction), or from the 
user’s data each time miRDeep is run.  In the following definitions, note that 
miRDeep uses the terms “mature” microRNA and “star” microRNA to refer to the 
two mature microRNAs birthed from a single hairpin.  These terms are confusing 
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due to the fact that both “mature” and “star” refer to mature microRNAs.  
MiRDeep simply assigns “mature” to the highest expressed sequence and “star” 
to the complementary sequence, adjusting for the 3' overhangs.   
 
Software published with the original miRDeep paper (Friedlander et al., 2008) is 
a set of seven Perl scripts that are to be run in sequence and therefore miRDeep 
can be run on any platform that supports Perl, e.g. Linux and Mac OS. MiRDeep 
requires as input the locations of aligned reads and the code is written to accept 
megaBLAST alignment output.  I have rewritten part of the miRDeep code to 
accept Bowtie alignment output since Bowtie guarantees finding the best 
alignment whereas megaBLAST uses a heuristic algorithm.  MiRDeep software 
can be run with a number of user-defined options and includes a permutation 
method to estimate the false positive rate.   
 
Running miRDeep without pre-filtering reads for known miRNAs allows the user 
to estimate performance statistics, including sensitivity and false positive rate.  
Although miRDeep includes a permutation method to estimate the false positive 
rate, a better estimation method may be to use the percentage of miRDeep 
predictions that overlap with annotated non-miRNAs (e.g. snoRNAs).  Sensitivity 
can be defined as the number of known microRNAs with aligned reads that are 
also predicted as microRNAs by miRDeep.  Novel microRNA predictions can be 
validated experimentally. 
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2.2.5 mirAnalyzer 
A microRNA prediction algorithm that uses a distinct approach from that of 
miRDeep is mirAnalyzer.  Instead of using positional information from an 
alignment, it uses unique read sequences and counts for each unique read 
sequence.  As opposed to using a Bayesian approach, it uses random forest, a 
machine learning algorithm.  MirAnalyzer is run as a web service and returns the 
expression of known microRNAs and novel microRNAs separately.  One way to 
assess the performance of a microarray prediction algorithm is to measure 
sensitivity for predicting known microRNAs.  MirAnalyzer only predicts 
microRNAs that do not match known microRNA sequences, which makes it 
impossible to calculate this performance measure.  This is one disadvantage of 
mirAnalyzer compared to miRDeep, which can be run without any annotation 
provided. 
 
2.3 Results 
 
2.3.1 Study Design 
An overview of the study design is shown in Figure 1: Overview of Novel 
microRNA Discovery.  Bronchial epithelium samples were obtained from 12 
individuals by taking brushings from the right main stem bronchus during 
bronchoscopy.  Small RNA was isolated, SOLiD libraries were prepared, and 
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libraries were sequenced using ABI SOLiD.  The sequencing produced 268 
million 36 base pair reads that were aligned to the human genome (UCSC 
version hg19, also known as Genome Reference Consortium GRCh37) using 
Bowtie (Langmead et al., 2009).  MicroRNAs were predicted de novo from 
aligned reads using miRDeep (Friedlander et al., 2008).  MiRDeep predicted both 
known and novel microRNAs.  The known microRNAs were filtered out and the 
highest scoring, unannotated predicted microRNA was selected for validation. 
 
 
Figure 1: Overview of Novel microRNA Discovery 
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2.3.2 Alignment Results  
For novel microRNA prediction, RNA-seq reads were aligned to the human 
genome (UCSC version hg19, also known as Genome Reference Consortium 
GRCh37) using stringent criteria in order to reduce the number of erroneous 
alignments.  Reads were aligned using Bowtie without allowing any mismatches 
and reads aligning to more than four locations in the genome were discarded due 
to suspicion that the reads were derived from repeat sequences.  Using these 
alignment parameters, 17.7 million reads were aligned and then used for novel 
microRNA prediction. 
 
Table 1: RNA-Seq Alignment Statistics 
Category Number of Reads 
Percentage of  
Total Reads 
Reads sequenced 268,059,777 100% 
Reads with at least 1 
alignment 
25,873,895 9.65% 
Reads that failed to align 233,973,859 87.28% 
Reads with alignments 
suppressed due to 
aligning to more than 4 
locations in the genome 
8,212,023 3.06% 
Reads used for novel 
microRNA prediction 
17,661,872 6.59% 
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2.3.3 Novel microRNA Prediction 
Novel microRNAs were predicted de novo from 17.7 million aligned reads using 
miRDeep and miRanalyzer.  MiRDeep was chosen to be the primary source of 
predictions as it gave the most detailed output, including the predicted locations 
of the pri-microRNAs (primary transcripts), pre-microRNAs (precursors), and 
mature microRNAs.  MiRDeep also gave a log-odds probability score to each 
predicted precursor.  In total, miRDeep predicted 450 miRNAs, including 258 
known microRNAs and 192 putative novel microRNAs (based on the current 
version of miRBase, v.16).  The 20 top-scored predictions are shown in Table 2.  
Only 1 of the 20 top-scored predictions, ranked ninth overall and first among 
novel predictions, was not a previously annotated microRNA.  This demonstrates 
that high ranked miRDeep predictions are rarely false positives.  This top-ranked, 
novel microRNA that was predicted by miRDeep was also predicted as a novel 
microRNA by mirAnalyzer.  
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Table 2: Top-Scored miRDeep Predictions  
Rank  
(by score) 
Mirbase v.16 
Annotation 
miRDeep-predicted miRNA 
Precursor Location 
miRDeep 
Score 
Expression 
(RPM) 
1 hsa-mir-34c chr11:111384176-111384230 603814.5 8074.260363 
2 hsa-mir-34b chr11:111383676-111383734 235518.6 6157.860064 
3 hsa-mir-99a chr21:17911421-17911479 142237.9 2122.560453 
4 hsa-mir-191 chr3:49058068-49058127 96606.2 1246.988485 
5 hsa-mir-429 chr1:1104400-1104456 62102.4 515.6618955 
6 hsa-mir-200a chr1:1103259-1103317 48046.6 535.0316799 
7 hsa-mir-145 chr5:148810224-148810284 25847.7 105.1451053 
8 hsa-mir-26b chr2:219267380-219267435 23304 276.6957471 
9 NONE chr1:85599490-85599545 20098.6 76.30685086 
10 hsa-mir-17 chr13:92002872-92002930 19943.7 311.4495409 
11 hsa-let-7c chr21:17912158-17912224 19464.3 189.7301042 
12 hsa-mir-130a chr11:57408685-57408746 15403 169.981581 
13 hsa-mir-140 chr16:69967005-69967067 12142 261.1674562 
14 hsa-mir-30e chr1:41220043-41220106 11577.2 142.6402466 
15 hsa-mir-203 chr14:104583768-104583827 10980.1 152.4513851 
16 hsa-mir-148b chr12:54731024-54731082 7272.3 33.47329596 
17 hsa-mir-20a chr13:92003326-92003384 7223.2 85.63103944 
18 hsa-mir-185 chr22:20020676-20020731 6771 82.52898831 
19 hsa-mir-660 chrX:49777864-49777921 6524.8 47.27020943 
 
2.3.4 Computational Validation of Top-Scored Novel microRNA Prediction 
The top-scored novel microRNA prediction was further investigated 
computationally to see if it exhibited the characteristics of known microRNAs.  
For this analysis, RNA-seq reads were aligned to the human genome allowing up 
to two mismatches (as opposed to the alignment used for microRNA prediction, 
which did not allow mismatches) to allow reads containing sequencing errors and 
small sequence variation to be aligned and investigated.  The aligned reads in 
the region of the predicted microRNA were then visualized using the UCSC 
Genome Browser (Kent et al., 2002; Meyer et al., 2013).  The expression profile 
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shown in Figure 2 lends confidence to the prediction as the profile is 
characteristic of known microRNAs.  Most importantly, the regions of highest 
expression (Figure 2A) match the miRDeep predictions of the locations of mature 
microRNAs, as should be the case for a correct prediction.  As is also typical of 
known microRNAs, there is a small amount of variation (up to 1 nucleotide) in the 
location of the 5’ ends (the left ends of the mature microRNAs in Figure 2A) and 
a larger amount of variation (up to 5 nucleotides) in the location of the 3’ ends of 
the predicted microRNAs (the right ends of the mature microRNAs in Figure 2A).  
This phenomenon of varied 5’ and 3’ end locations is a product of Dicer 
processing of microRNA precursors, which is sometimes described as “fuzzy” 
(Friedlander et al., 2008). 
 
An important hallmark of microRNA precursors is that they fold into hairpins.  
Therefore, in order to establish whether or not the miRDeep-predicted novel 
microRNA has this quality, we have computationally predicted the structure of the 
miRDeep-predicted precursor sequence using RNAfold (Figure 3).  The predicted 
secondary structure is in fact a hairpin and includes the sequences of the 
predicted 3p and 5p mature microRNAs.  The predicted structure also displays 
the 2 nucleotide overhangs at the 3' end of each mature microRNA that is 
characteristic of known microRNAs.  Taken together, these findings based on the 
predicted secondary structure lend confidence to the hypothesis that the 
miRDeep-predicted novel microRNA is in fact a microRNA. 
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Figure 2: Expression Profile of miRDeep-Predicted Novel microRNA and 
DNA Sequence Conservation Across Mammals 
A) Expression profile created by aligned RNA-seq reads in units of reads per million reads 
sequenced (RPM) 
B) Predicted locations of microRNA primary transcript (grey), 5p and 3p mature microRNAs 
(black), and mature microRNA seeds (red and blue for 5p and 3p, respectively). 
C) Conservation of human DNA sequence in the region of the putative novel microRNA 
across 23 mammalian species based on MULTIZ alignment (Blanchette et al., 2004).  
The human DNA sequence is shown at the top.  The 23 non-human mammalian species 
from top to bottom are: chimpanzee, gorilla, orangutan, rhesus, baboon, marmoset, 
mouse lemur, bush baby, tree shrew, mouse, rat, guinea pig, rabbit, pika, alpaca, 
dolphin, dog, microbat, megabat, elephant, rock hyrax, armadillo, and sloth.  For use of 
reading, in the non-human species the conserved bases are labeled as “.”, deletions are 
labeled as “-“, and insertions are labeled as “|” with the number of bases inserted shown.  
 
 
Figure 3: Predicted Secondary Structure of the Putative Novel microRNA 
Precursor Sequence 
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2.3.5 Evolutionary Conservation of Putative Novel microRNA 
MicroRNAs are commonly well conserved across species and therefore we have 
looked at evolutionary conservation of the predicted novel microRNA primary 
sequence, precursor sequence, mature microRNA sequences, and mature 
microRNA seed sequences.  Figure 2C shows the conservation of these human 
sequences across 23 mammalian species.  The primary, precursor, and mature 
microRNA sequences are well conserved across simians, a subset of the 
primates, but they are not conserved in the other mammals.  For the human 
genome region spanning from 85599470-8559990, there is no corresponding 
alignment in non-simian mammals.  This suggests that the putative microRNA 
evolved recently as part of an insertion event.   
 
In order to explore whether the putative microRNA is functionally conserved in 
the genomes of nonhuman simians, we have undertaken a quantitative analysis 
of the degree of conservation of the putative microRNA in chimpanzee, 
orangutan, rhesus, and marmoset.  If the microRNA is conserved in a given 
species, e.g. chimpanzee, the chimpanzee sequence that is homologous to the 
human precursor should fold into a hairpin and therefore have a low folding 
energy.  In addition, the chimpanzee sequence homologous to the mature 
microRNA seed region (bases 2-8) should be identical as the seed region 
sequence determines target specificity.  The sequence corresponding to the 
entire mature microRNA and precursor in chimpanzee should also be similar to 
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the human sequence.  Given that folding of the microRNA precursor is a 
determinate of mature microRNA production, the chimpanzee sequence 
homologous to the human precursor should fold in approximately the same way 
as the human precursor sequence. 
 
Pairwise sequence and structural similarities between the human microRNA 
sequence and homologous sequences in chimpanzee, orangutan, rhesus, and 
marmoset were computed and the folding energies of the human precursor and 
homologous sequences were calculated.  The results of these analyses are 
summarized in Table 3.  In all species analyzed, the sequence homologous to 
the precursor has a low folding energy, suggesting hairpin structures that are 
characteristic of microRNAs.  The chimpanzee and orangutan sequences are 
very similar to the human sequence, with over 90% sequence similarity over the 
precursor and 100% sequence similarity for the 3p and 5p seed regions.  This 
suggests that the chimpanzee and orangutan genomes code for microRNAs that 
are functionally identical to the 3p and 5p microRNAs found in the human 
genome.   
 
The rhesus and marmoset sequences are less similar to the human sequence 
than the chimpanzee and orangutan sequences are.  In rhesus, the 
corresponding sequence to the human 3p mature microRNA appears to be 
conserved but the corresponding sequence to the human 5p mature microRNA 
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seed is different by 1 nucleotide.  This suggests that the rhesus sequence 
corresponding to the human precursor contains one mature microRNA that is 
functionally identical to the human 3p mature microRNA and one mature 
microRNA that has a different function from the 3p and 5p human mature 
microRNAs.  In marmoset, the corresponding sequence to the human 3p mature 
microRNA appears to be conserved but the corresponding sequence to the 
human 5p mature microRNA only has 62% similarity to the human homolog.  
This suggests that, like in rhesus, the marmoset sequence corresponding to the 
human precursor contains one mature microRNA that is functionally identical to 
the human 3p mature microRNA and one mature microRNA that has a different 
function from the 3p and 5p human mature microRNAs. 
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Table 3: Quantitative Analysis of miR-4423 Conservation in Select Primates 
Analysis of predicted RNA folding energy, predicted RNA secondary structure similarity, and 
sequence similarity between the predicted precursor, mature microRNA, and mature microRNAs 
seed sequences in human and select nonhuman simians.  Cutoffs listed for defining conservation 
are merely guidelines based on Persson et al (Persson et al., 2011).  See methods for detailed 
explanation of calculations. 
Species Conservation 
Structure Sequence Similarity 
Folding 
Energy 
Structure 
Distance 
Precursor 
3p 
(full) 
5p 
(full) 
3p 
seed 
5p 
seed 
CUTOFF  < -20 < 35 > 0.4 > 0.85 > 0.85 = 1 = 1 
Chimpanzee Yes (Both) -20.4 0 0.96 1.00 1.00 1.00 1.00 
Orangutan Yes (Both) -21.9 10 0.93 1.00 1.00 1.00 1.00 
Rhesus 3p only -29.7 20 0.75 0.62 0.62 1.00 0.83 
Marmoset 3p only -29.4 22 0.82 0.71 0.71 1.00 1.00 
 
 
2.3.6 Comparison of Putative Mature Novel microRNA Seed Sequences 
With Seed Sequences of Known microRNAs 
A common feature of microRNAs is having shared seed sequences with other 
microRNAs.  The method used for finding shared seed sequences was to identify 
exact matches to the novel microRNA 3p and 5p seed sequences (bases 2-7) in 
all miRBase version 17 seed sequences across all species.  The novel 
microRNA 3p seed is only shared with one microRNA in miRBase 17, which is 
from silkworm (bmo-miR-3308*).  The novel microRNA 5p seed is shared with 
one herpes virus microRNA (hsv1-miR-H4*) and two recently discovered human 
microRNAs (hsa-miR-3152-5p, hsa-miR-4774-3p).  In summary, the 3p and 5p 
seed sequences of the novel microRNA are not shared by any nonhuman 
mammals. 
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2.3.7 Experimental Validation and Characterization  
The predicted novel microRNA was experimentally validated and characterized 
by Catalina Perdomo, Joshua Campbell, Carly Garrison, and other collaborators.  
They demonstrated that miR-4423 is highly expressed in mucociliary epithelium, 
including bronchial and nasal epithelium, and lowly expressed or undetectable in 
most other tissues.  Ectopic expression of miR-4423 in lung cancer cell lines 
reduced tumor size in a mouse xenograft model and anchorage independent 
growth in vitro.  Expression of miR-4423 is decreased in most lung tumors and 
the normal bronchial epithelium of subjects with lung cancer. 
 
2.4 Discussion 
 
The main goal of this project was to use data from RNA-seq of bronchial 
epithelium, a clinically relevant tissue for lung cancer diagnosis, to produce a 
single, high quality novel microRNA prediction for validation and characterization.  
The novel microRNA prediction from this analysis was experimentally validated 
and found to be primate specific and associated with lung cancer in airway 
development.  We have RNA-sequenced small RNA from samples obtained via 
bronchial brushings taken during bronchoscopy.  Using two microRNA prediction 
algorithms, miRDeep and mirAnalyzer, a number of novel microRNAs were 
predicted and the top-scored predicted novel microRNA was investigated further.  
Additional computational analysis added evidence suggesting validity of the 
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candidate novel microRNA.  The expression profile visualized using the UCSC 
genome browser (Figure 2) matched the predicted microRNA location and the 
expression pattern of known microRNAs.  Computational secondary structure 
prediction of the candidate precursor sequence resulted in a hairpin structure, 
which is characteristic of microRNA precursors.  Using DNA sequence alignment, 
I showed that this microRNA is only conserved in simians, a subset of the 
primates.  In addition, the seed sequences of the mature 3p and 5p microRNAs 
are not shared by any nonhuman mammals.  This suggests that the targeting 
and thereby function of this microRNA is separate from previously discovered 
microRNAs. 
 
The miRDeep score, which is partially based on expression level, was used to 
rank novel microRNA predictions from most confident to least confident.  Using 
this ranking, all but 1 of the top 20 predictions were known microRNAs, showing 
that the top-scoring miRDeep predictions are rarely false positives.  The top-
scoring novel microRNA prediction from miRDeep was also predicted as a novel 
microRNA by mirAnalyzer.  Given these computational results, we felt confident 
in selecting the top-scoring miRDeep prediction for experimental validation.   
 
An interesting feature of the RNA-seq expression profile of the novel mature 
microRNAs is the variation in the exact starting and ending nucleotides of the 
sequences.  This type of variation appears to be common to many mature 
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microRNAs and the biogenesis and biological role of these isoforms, termed 
isomirs, is an intense area of research.  A recent review tried to summarize 
current knowledge of isomirs (Ameres and Zamore, 2013).  The expression 
profile indicates that a number of different isomirs of the microRNA are stable.  
Differential isomir usage has been identified.  Variation in the 5' end would likely 
have a larger impact than variation in the 3' end given that the seed sequence, 
which is the strongest determinant of target recognition, changes based on the 
start of the 5' end. 
 
During the course of this write up, after novel microRNA prediction and 
validation, the approximate location of the predicted novel microRNA precursor 
was annotated in miRDeep v. 17 as miR-4423.  The predicted novel microRNA 
3p seed sequence is the same as the hsa-miR-4423-3p seed sequence.  
However, the predicted novel microRNA’s 5p seed sequence differs from the 
annotated miR-4423-5p seed sequence in that miR-4423-5p has an additional 
adenine at the 5’ end.  As seed sequence is a major determinant of microRNA-
mRNA target recognition, the miRDeep prediction provides information not 
available in miRBase.  The difference in seed sequence may be cell type specific 
and reflect microRNA processing specific to bronchial epithelial cells.   
 
The predicted novel microRNA has the potential to be a biomarker for lung 
cancer given that its expression is decreased in the airways of smokers with lung 
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cancer vs. smokers without lung cancer.  A current study underway is using 
RNA-seq to profile miR-4423 and all microRNAs in the bronchial epithelia of 
smokers with and without lung cancer.  We are in the process of building 
microRNA and combined microRNA-mRNA biomarkers that may outperform our 
published bronchial mRNA biomarker.  We also plan to investigate the potential 
for microRNA expression in nasal epithelium to be used in a minimally invasive, 
lung cancer screening test for patients with indeterminate nodules. 
 
2.5 Methods 
 
Patient Population and Sample Collection 
Bronchial epithelial cells were obtained from 12 individuals via bronchial 
brushings during bronchoscopy.  We recruited never (n = 3) and current (n = 3) 
smokers who underwent fiberoptic bronchoscopy as volunteers at Boston 
University Medical Center (BUMC), as well as current and former smokers with 
suspected lung cancer (n = 6) undergoing bronchoscopy during lung nodule 
resection.  
 
Small RNA Sequencing 
Samples from the 12 subjects were pooled and then size fractioned using the 
Ambion flashPAGE fractionator to obtain small RNAs ranging in length from 10 -
40 nucleotides.  Small RNA sequencing libraries were created using SOLiD 
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Small RNA Expression Kit (Ambion) starting with 200ng of the size fractionated 
material and following the manufacturer’s instructions.  Libraries were sequenced 
on an Applied Biosystems SOLiD System to obtain 36 base pair reads. 
 
Computational Prediction of Novel microRNAs  
Small RNA sequencing data were examined for transcripts that had a canonical 
microRNA structure but did not map to known microRNA loci using the miRDeep 
algorithm.  
 
Conservation Analysis 
The homologous region to the novel microRNA precursor was identified for each 
species (chimpanzee, orangutan, rhesus, and marmoset) using UCSC LiftOver.  
The folding energy of the human precursor and corresponding regions in the 
nonhuman simians was calculated using RNAfold.  Note that high conservation 
minimizes RNA distance (0 = identical) and maximizes sequence similarity (1.00 
= 100% identical).  Low folding energy (E < -20kcal) indicates a favorable hairpin 
structure.  For the precursor, sequence similarity was calculated using 
Needleman-Wunsch global alignment (match = 1, gap = -1, mismatch = -1) and 
structure distance was calculated using RNAdistance.  Sequence similarity was 
calculated for the 3p and 5p mature microRNAs and their seed regions using 
Smith-Waterman local alignment (match = +1, gap = -1, mismatch = -1). 
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3. Nasal Epithelial Gene Expression Differences Between Subjects With 
and Without Lung Cancer and Its Use As an Early Detection Biomarker 
 
3.1 Introduction 
 
Lung cancer surpasses all other causes of cancer-related deaths worldwide.  The 
most recent figure for the five-year, lung cancer survival rate is only 17.3%.  This 
low survival rate is partly due to the lack of effective, minimally invasive 
diagnostic and screening tools.  Our group previously developed a bronchial 
gene expression biomarker for lung cancer diagnosis.  We also measured 
smoking-related gene expression in bronchial and nasal epithelia and found 
similarities in the gene expression response of the two tissue types.  Given these 
two pieces of evidence, that there is a field effect associated with lung cancer 
that extends to normal bronchial epithelium and that smoking-related gene 
expression is similar in bronchial and nasal epithelium, we have hypothesized 
that the cancer field also extends to nasal epithelium.  There are two settings 
where a nasal gene expression test for lung cancer may be useful: 1) the 
diagnostic setting, where patients are already under suspicion for lung cancer 
due to radiographic abnormalities and/or symptoms, and 2) the screening setting, 
where subjects are healthy individuals at high-risk for lung cancer.  This chapter 
describes analysis of nasal epithelial gene expression in the diagnostic setting. 
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Here we detail our exploration of nasal epithelial gene expression differences 
between subjects with and without lung cancer and development of a diagnostic 
biomarker. 
 
3.2 Background 
 
3.2.1 Microarrays for Profiling Gene Expression  
Data noisiness is an important issue that needs to be addressed as a part of 
solving the classification problem.  Normalization can be used to adjust for this 
common dilemma.  In fact, normalization may be the difference between success 
and failure, especially with the challenge of batch effects.  The evolution of 
microarray technology has required an evolution of normalization methods.  
Earlier designs of the popular Affymetrix GeneChip contain perfect match and 
mismatch probes for each transcript and this information could be used by the 
popular MAS normalization algorithms.  The current line of Affymetrix 
microarrays does not contain mismatch probes for each transcript and different 
normalization methods must be used for this type of platform.  There are a 
number of methods to address the normalization challenge given by the new 
types of microarrays.  The most popular method appears to be Robust Multichip 
Average (RMA) (Bolstad et al., 2003; Irizarry et al., 2003a; Irizarry et al., 2003b), 
which was published 10 years ago.  RMA uses quantile normalization to adjust 
the expression values across the arrays.  New approaches have been published 
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recently, such as frozen RMA (fRMA, McCall et al., 2010).  Whereas RMA 
requires normalization of a batch of arrays together, fRMA allows for single array 
normalization.  This makes fRMA especially appealing for biomarker validation. 
 
3.2.2 Overview of Gene Expression Biomarkers 
The classification of disease phenotype based on gene expression microarray is 
a fruitful area of research (Golub et al., 1999; Spira et al., 2007).  There are 
multiple challenges in using microarray data for classification, including handling 
the p >> n problem, where the number of predictors, p (i.e. genes) ranges in the 
tens of thousands but the number of samples, n, in a typical study ranges in the 
tens to hundreds.  The p >> n challenge makes feature selection especially 
important. 
  
An early example of a gene expression biomarker was published by Golub et.al., 
2001.  They showed the ability to differentiate between types of leukemia using 
gene expression and a simple classification rule.  Since then, a number of other 
algorithms have been developed and successfully applied to the setting of gene 
expression.  These include random forest, support vector machines, and top 
scoring pairs.  Each of these algorithms operates under a unique principle.  The 
success of one algorithm over another is not obvious before applying them to a 
given dataset. 
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Mammaprint and Oncotype Dx are two common gene expression-based 
diagnostic tools that are currently used in clinics (Paik, 2007; Paik et al., 2004; 
van 't Veer et al., 2002; van de Vijver et al., 2002).  Both of these technologies 
use gene expression from human breast cancer samples to predict the likelihood 
of recurrence and influence the patient's decision about whether it is necessary 
to undergo chemotherapy.  Interestingly, these biomarkers give different output -
MammaPrint produces a binary output of high likelihood vs. low likelihood 
whereas Oncotype DX produces a risk score.  An output of high vs. low likelihood 
involves applying a threshold to a classification score and therefore contains less 
information than the score itself.  However, which type of output is better 
depends on the ability of the clinician and patient to effectively incorporate the 
classifier output into decision-making.  
 
3.2.3 An 80-Gene Bronchial Gene Expression Biomarker for Lung Cancer 
Diagnosis and a Prediction Model That Integrates Gene Expression and 
Clinical Risk Factors 
In a 2007 paper published in Nature Medicine, Spira et al. showed that gene 
expression in cytologically normal bronchial epithelium can be used to diagnose 
lung cancer.  The biomarker was developed and tested in the clinically relevant 
cohort of current and former smokers undergoing clinical evaluation for suspicion 
of lung cancer.  The standard test that clinicians use to evaluate these subjects is 
bronchoscopy, which involves putting a flexible tube down the airway and 
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collecting bronchial cells.  The collected cells are then cytologically examined in 
order to identify the presence or absence of cancerous cells.  However, this 
cytopathology method lacks sensitivity, especially for small or peripheral tumors 
that cannot be sampled via bronchoscopy.  
 
For the subjects in the study, bronchial epithelial cells were obtained via 
bronchial brushing during bronchoscopy.  Then the samples were hybridized 
onto Affymetrix HG-U133A whole-genome gene expression microarrays.  Within 
the training set (n = 77), the signal-to-noise statistic (Golub et al., 1999) was used 
to select 80 genes that best discriminated cases from controls.  Using this 80-
gene committee, weighted voting was used to develop a classifier that validated 
on an independent test set (n = 53, 80% sensitive, 84% specific) and a separate 
validation set (n = 35).  Importantly, when the biomarker result for each subject 
was combined with cytopathology, the combined biomarker yielded 95% 
sensitivity and 95% negative predictive value. 
 
The clinical utility of a gene expression biomarker depends on its independence 
from clinical risk factors that are routinely available.  Beane et al. demonstrated 
that the 80-gene, bronchial gene expression biomarker described above is 
independent from clinical risk factors (Beane et al., 2008).  Specifically, the 
authors showed that the bronchial gene expression biomarker is predictive of 
lung cancer independent from the traditional clinical risk factors of mass size, 
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lymphadenopathy, age, and smoking status (current smoker or former smoker).  
In this case, the gene expression biomarker was developed independently from 
clinical factors and then later combined into a prediction model with clinical 
factors.  Another way to construct clinico-genomic biomarkers is to combine the 
clinical and gene expression features and use the clinical features to guide gene 
selection.  For instance, Pittman et al. used decision trees that incorporated both 
gene expression and clinical features (Pittman et al., 2004). 
 
3.3 Results 
 
3.3.1 Study Design 
Samples containing nasal epithelial cells were collected from each subject via 
brushing the right nasal inferior turbinate at each subject’s initial visit.  Clinical 
diagnoses were recorded for the study at 3 months and 12 months after the initial 
visit; and the 12 month diagnosis was used for biomarker development.  Gene 
expression data was generated for each sample using Affymetrix Human 
Genome 1.0 ST microarrays.  An overview of the clinical evaluation, sample 
collection, and data generation is shown in Figure 4. 
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Figure 4: Overview of Clinical Evaluation, Sample Collection and Data 
Generation 
 
3.3.2 Study Population 
Subjects included in the study were patients under clinical evaluation for 
suspicion of lung cancer who were current or former smokers, had a radiographic 
abnormality seen on imaging of the chest, and were undergoing clinically 
indicated bronchoscopy.  The exclusion criteria were history of any kind of cancer 
or nasal disease.  Microarray data was available for a total of 307 nasal samples 
from 306 unique subjects.  The inclusion and exclusion criteria and quality 
filtering were applied to all available data in order to derive training, test, and 
validation sets.  Only the training set was used for gene expression analysis and 
biomarker development.  
 
An overview of the way that the training, test, and validation sets were derived 
from all available microarray data is shown in Figure 5.  Microarrays were 
processed at two different times, separated by over a year: February 2011 and 
43 
 
July 2012.  The training and test sets consist of microarray data generated in July 
2012 whereas the validation set consists of microarray data generated in 
February 2011.  Microarray data from both time points were filtered by applying 
the same, standard microarray quality control filters (see methods section for 
details).  The training, test, and validation sets are balanced for covariates that 
may affect gene expression, namely smoking status (current or former), 
cumulative tobacco exposure (measured by pack-years), age, gender, 
microarray batch, and RIN (an RNA quality score generated from a Bioanalyzer 
2100 Instrument).  The subject demographics for each dataset are shown in 
Tables 4-6. 
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Figure 5: Derivation of the Training, Test, and Validation Sets 
The same quality control procedure was used for microarray data generated in July 2012 and 
February 2011.  A) Derivation of the training and test sets from microarray data generated in July 
2012.  B) Derivation of the validation set from microarray data generated in February 2011. 
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Table 4: Subject Demographics, Sample Quality, and Batch Distribution for 
Training Set Samples 
The training set is balanced for covariates that affect gene expression, namely smoking status, 
pack-years, gender, age, batch, and RIN.  P-values were determined by Fisher exact test for the 
categorical variables and Welch t-tests for the continuous variables. 
 CANCER CONTROL P 
CURRENT 20 (29.4%) 9 (31%) 0.93 
FORMER 48 (70.6%) 20 (69%)  
    
PY 40.9 +/- 28.4 37.8 +/- 36 0.68 
    
FEMALE 24 (35.3%) 9 (31%) 0.86 
MALE 44 (64.7%) 20 (69%)  
    
AGE 58.2 +/- 8.44 54.9 +/- 11.9 0.18 
    
RIN 
5.2  
+/- 1.74 
4.72 +/- 1.83 0.24 
    
BATCH   0.92 
1 13 (19%) 5 (17%)  
2 11 (16%) 7 (24%)  
3 14 (21%) 6 (21%)  
4 13 (19%) 5 (17%)  
5 17 (25%) 6 (21%)  
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Table 5: Subject Demographics, Sample Quality, and Batch Distribution for 
Test Set Samples 
The test set is balanced for covariates that affect gene expression, namely smoking status, pack-
years, gender, age, batch, and RIN.  P-values were determined by Fisher exact test for the 
categorical variables and Welch t-tests for the continuous variables. 
  CANCER CONTROL P 
CURRENT 10 (43.5%) 3 (30%) 0.70 
FORMER 13 (56.5%) 7 (70%)   
        
PY 
42.7  
+/- 25.6 
28.2  
+/- 30.1 
0.2 
        
FEMALE 8 (34.8%) 3 (30%) 1 
MALE 15 (65.2%) 7 (70%)   
    
AGE 
54.9  
+/- 6.43 
58.2  
+/- 11.6 
0.41 
        
RIN 5.03 +/- 1.45 4.87 +/- 2.31 0.84 
    
BATCH     0.73  
1 3 (13%) 2 (20%)  
2 3 (13%) 2 (20%)   
3 7 (30%) 1 (10%)   
4 4 (17%) 3 (30%)   
5 6 (26%) 2 (20%)   
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Table 6: Subject Demographics, Sample Quality, and Batch Distribution for 
Validation Set Samples 
The validation set is balanced for covariates that affect gene expression, namely smoking status, 
pack-years, gender, age, batch, and RIN.  P-values were determined by Fisher exact test for the 
categorical variables and Welch t-tests for the continuous variables. 
 CANCER CONTROL P 
CURRENT 17 (41.5%) 3 (33.3%) 0.72 
FORMER 24 (58.5%) 6 (66.7%)   
        
PY 18.2 +/- 9.69 22.1 +/- 13.9 0.45 
        
FEMALE 20 (48.8%) 3 (33.3%) 0.48 
MALE 21 (51.2%) 6 (66.7%)   
        
AGE 
64.9  
+/- 13 
54  
+/- 14.5 
0.06 
        
RIN 4.16 +/- 1.64 3.9 +/- 1.75 0.69 
    
BATCH     0.10  
A 15 (37%) 1 (11%)  
B 8 (20%) 0 (0%)   
C 5 (12%) 3 (33%)   
D 13 (32%) 5 (56%)   
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Table 7: Subject Demographics, Sample Quality, and Batch Distribution for 
Samples in the Combined Set 
The combined set (i.e. the combination of the test set and validation set samples) is balanced for 
covariates that affect gene expression, namely smoking status, pack-years, gender, age, batch, 
and RIN.  P-values were determined by Fisher exact test for the categorical variables and Welch 
t-tests for the continuous variables. 
 CANCER CONTROL P 
CURRENT 27 (42.2%) 6 (31.6%) 0.44 
FORMER 37 (57.8%) 13 (68.4%)   
        
PY 25.5 +/- 13.7 30.9 +/- 18.1 0.24 
        
FEMALE 28 (43.8%) 6 (31.6%) 0.43 
MALE 36 (56.2%) 13 (68.4%)   
        
AGE 
61.3 
+/- 12.1 
56.2  
+/- 12.9 
0.14 
        
RIN 4.47 +/- 1.62 4.41 +/- 2.07 0.9 
    
DATASET     0.29  
Validation 41 (64%) 9 (47%)  
Test 23 (36%) 10 (53%)   
 
 
3.3.3 Differentially Expressed Genes in the Nasal Epithelium Between the 
Lung Cancer Group and Control Group   
Using only the training set samples and a significance level of 0.005, 194 genes 
were identified by Welch t-test as differentially expressed between the cancer 
and control groups (114 were downregulated in the cancer group and 80 were 
upregulated in the cancer group).  A heat map with the differentially expressed 
genes is shown in Figure 6.  Inside the heat map, subjects are arranged by 
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unsupervised hierarchical clustering.  There is a separation between the cancer 
subjects, most of which cluster on the left-hand side, and the controls, most of 
which cluster on the right-hand side. 
 
 
Figure 6: Heat Map of 194 Differentially Expressed Genes in the Nasal 
Epithelium Between the Cancer and Control Groups 
Expression levels of the 194 genes in the 97 training set samples, where each row is a gene and 
each column is a sample.  Both the rows (genes) and columns (samples) are organized by 
unsupervised hierarchical clustering (the dendrogram is only shown for the samples).  The top 
row of the heat map displays the cancer status of each subject.  Expression values were z-score 
normalized per gene. 
 
3.3.4 Gene Ontology Enrichment for Differentially Expressed Genes in the 
Nasal Epithelium Between the Cancer and Control Groups 
In order to achieve an understanding of the biological functions of the 
differentially expressed genes, we utilized GATHER (Chang and Nevins, 2006) to 
test for enrichment in Gene Ontology (GO) terms (Ashburner et al., 2000).  
Genes upregulated in the cancer group were enriched for GO terms related to 
organogenesis, cell adhesion, and morphogenesis (Table 8); whereas genes 
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downregulated in the cancer group were enriched for GO terms related to 
immune response and endogenous antigen presentation (Table 9). 
 
Table 8: Enriched Gene Ontology Terms Among Genes Upregulated in the 
Cancer Group 
# GO Category 
Number 
of DE 
Genes 
Within 
Category 
Total 
Number 
of Genes 
in GO 
Category 
Within 
Genome 
ln (Bayes 
factor) 
1 
GO:0009887 [4]: 
organogenesis 18 906 12.3 
2 
GO:0048513 [3]: organ 
development 18 906 12.3 
3 
GO:0007155 [4]: cell 
adhesion 14 568 11.15 
4 
GO:0007275 [2]: 
development 24 1763 10.91 
5 
GO:0009653 [3]: 
morphogenesis 19 1131 10.68 
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Table 9: Enriched Gene Ontology Terms Among Genes Downregulated in 
the Cancer Group 
# GO Category 
Number 
of DE 
Genes 
Within 
Category 
Total 
Number 
of Genes 
in GO 
Category 
Within 
Genome 
ln (Bayes 
factor) 
1 
GO:0006955 [4]: immune 
response 22 725 19.93 
2 
GO:0006952 [5]: defense 
response 22 816 17.73 
3 
GO:0009607 [4]: response 
to biotic stimulus 23 935 17.04 
4 
GO:0019883 [6]: antigen 
presentation, endogenous 
antigen 5 7 15.26 
5 
GO:0019885 [6]: antigen 
processing, endogenous 
antigen via MHC class I 5 7 15.26 
 
 
3.3.5 KEGG Pathway Enrichment 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a knowledge base 
that includes well-curated biological pathways (Kanehisa and Goto, 2000; 
Kanehisa et al., 2012) which are also stored in the Molecular Signatures 
Database (MSiGDB) (Subramanian et al., 2005).  Gene Set Enrichment Analysis 
(Subramanian et al., 2005) was used to identify KEGG pathway gene sets that 
are concordantly upregulated or downregulated in the cancer vs. control group.  
The ranked list for GSEA was generated from the nasal training set (a Welch t-
test between the cancer and control group values was performed for each of the 
~20,000 genes and the genes were ranked by t-statistic).  At a significance level 
of FDR q-value 0.25, 5 gene sets were positively enriched in the cancer group, 
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including basal cell carcinoma (Table 10), and 69 gene sets were negatively 
enriched in the cancer group, the top 5 of which are listed in Table 11.  Many of 
the gene sets negatively enriched in the cancer group are related to immune 
response. 
 
Table 10: KEGG Pathway Gene Sets Positively Enriched in the Cancer 
Group by GSEA      
Rank 
KEGG Pathway 
Gene Set 
Size ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
Rank 
At 
Max 
Leading 
Edge 
1 RIBOSOME 76 0.64 2.81 0 0 0 4022 
tags=61%, 
list=20%, 
signal=76% 
2 
ECM 
RECEPTOR 
INTERACTION 
83 0.45 1.98 0 0.008 0.024 3574 
tags=35%, 
list=18%, 
signal=42% 
3 
BASAL CELL 
CARCINOMA 
55 0.46 1.89 0 0.013 0.052 1273 
tags=29%, 
list=6%, 
signal=31% 
4 
GLYCINE 
SERINE AND 
THREONINE 
METABOLISM 
31 0.46 1.69 0.002 0.067 0.315 780 
tags=19%, 
list=4%, 
signal=20% 
5 
HEDGEHOG 
SIGNALING 
PATHWAY 
56 0.38 1.57 0.005 0.144 0.648 1258 
tags=21%, 
list=6%, 
signal=23% 
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Table 11: KEGG Pathway Gene Sets Negatively Enriched in the Cancer 
Group by GSEA     
Rank 
KEGG Pathway 
Gene Set 
Size ES NES 
NOM 
p-val 
FDR 
q-
val 
FWER 
p-val 
Rank 
At 
Max 
Leading 
Edge 
1 
ANTIGEN 
PROCESSING 
AND 
PRESENTATION 
79 -0.6 -2.6 0 0 0 2704 
tags=49%, 
list=14%, 
signal=57% 
2 
GRAFT VERSUS 
HOST DISEASE 
36 -0.7 -2.6 0 0 0 4536 
tags=83%, 
list=23%, 
signal=108% 
3 PROTEASOME 43 -0.7 -2.5 0 0 0 4788 
tags=74%, 
list=24%, 
signal=98% 
4 
INTESTINAL 
IMMUNE 
NETWORK FOR 
IGA 
PRODUCTION 
46 -0.6 -2.4 0 0 0 4390 
tags=67%, 
list=22%, 
signal=86% 
5 
VIRAL 
MYOCARDITIS 
68 -0.6 -2.4 0 0 0 4435 
tags=57%, 
list=22%, 
signal=74% 
 
 
3.3.6 The Lung-Cancer-Associated Nasal Epithelial Cell Gene Expression 
Signature Is Enriched in Bronchial Epithelial Cell Gene Expression From 
the Same Subjects 
GSEA was used to test for enrichment between lung-cancer- associated gene 
expression in nasal and bronchial epithelium.  Gene sets from the 194 
differentially expressed genes in nasal epithelium were queried against a ranked 
list derived from bronchial gene expression data.  Two gene sets were created 
out of the list of 194 genes differentially expressed in nasal epithelium: one with 
the 80 genes upregulated in cancer and one with the 114 genes downregulated 
in cancer (corresponding to Figure 7: A and B, respecively).  Bronchial gene 
54 
 
expression data was available for 65 of the 97 subjects in the training set (46 
cancer and 19 control subjects) and was used to create the ranked list.  
Specifically, within the bronchial data, a Welch t-test between the cancer and 
control groups was performed across all genes measured by microarray 
(~20,000) and then the genes were ranked by t-statistic.  This ranked list 
corresponds to the x-axes of Figure 7: A and B, which are ordered from left to 
right by the genes whose expression is most positively to most negatively 
associated with lung cancer.  Both nasal gene sets were enriched in the 
bronchial ranked list at p < 0.001, establishing that there is a common, lung- 
cancer-associated gene expression signature throughout the airway that includes 
genes upregulated and downregulated with respect to lung cancer (Figure 7).   
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Figure 7: Enrichment of Lung-Cancer-Associated Nasal Epithelial Cell Gene 
Expression Signature in Bronchial Epithelial Cell Gene Expression From 
the Same Subjects 
Results from Gene Set Enrichment Analysis using a ranked list of lung cancer-associated gene 
expressions in bronchial epithelium.  A) The 80 genes most upregulated in the nasal epithelium 
are enriched in the positive direction at p < 0.001.  B) The 114 genes most downregulated in the 
nasal epithelium are enriched in the negative direction at p < 0.001. 
 
3.3.7 Biomarker Development Overview 
In this section we will describe the machine learning protocol that was used to 
develop a diagnostic biomarker for lung cancer, based on nasal gene expression 
measurements.  We initially sketch the procedure, and pursue a detailed 
development below. 
 
We took data in the form of nasal gene expression and built a learning machine 
that trained on a portion of the dataset (the training set), which was then tested 
on the remaining portion (the test set and validation set).  The goal was to 
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demonstrate that such a machine could be built to accurately guide diagnosis of 
lung cancer in the field, based on its performance on our test set and validation 
set. 
 
Different methods for constructing machines were evaluated on the training set.  
Each machine was specified by three parameters: 1) the gene selection method, 
2) the number of genes selected, and 3) the inducer, which is the type of 
machine (see below for description).  The options allowed for each parameter are 
listed in Figure 8.  The goals of biomarker development on the training set were 
to, 1) find the optimal parameters for constructing the final machine and 2) 
accurately estimate the future performance of the machine on samples 
independent from the training set. 
 
The inducer  represents the type of machine, selected from the following four 
choices: support vector machine (SVM-RFE), weighted voting (WV), random 
forest (RF), and naïve Bayes (NB).  Here SVM-RFE denotes the support vector 
machine (SVM) together with a proprietary feature selection method based on 
recursive feature elimination (RFE).  There were two choices for the gene 
selection method, , which are specified below in Figure 8.  These 
gene selection methods consisted of two types of t test, which in some cases 
were appended by further proprietary feature selection schemes (i.e., recursive 
feature selection in SVM, and tree-specific feature selection in RF).  Finally, the 
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decision on the reduced number of genes to be used as features in the machine 
learning algorithm involved selecting a fixed number of features, with  (number 
of features) taking the possible values  (see Figure 8).  In the 
cases where SVM-RFE was subsequently used to reduce the number of 
features, this number was lowered further. 
 
Having defined the restricted sets of choices for the parameters of the learning 
machine (those being the inducer , gene selection method , and number of 
genes ), the next step was to define a protocol (described below) to discover the 
best choice of parameters (only within  the training set).  The inducer was chosen 
first, followed by the gene selection method together with the reduced number of 
genes.  After the parameter definitions, the specific genes for the final feature set 
were selected and the final classifier was trained using the entire training set. 
 
3.3.8 Biomarker Development Protocol 
The choice of inducer was made using nested cross-validation (see pseudocode 
below in Figure 9).  For a current candidate inducer  (fixed for the moment) and 
current outstanding sub-test fold  (  in a 10-fold cross validation of 
the full training set, the following was done.  Within the current sub-training fold 
 (the complement of ) all allowed combinations of feature selection method 
 and allowed number of features  were tried in an LOOCV.  The top performing 
pair  (obtained from the LOOCV within the current training fold , 
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see pseudocode in Figure 10) was then used to train a classifier on the full 
training fold , which was then tested on the full test fold .  Thus for the 
current choice of fold , an AUC (area under the ROC curve) performance value 
for the candidate inducer  was obtained, for the above best choice of  
within that fold.  These performances were then averaged over the 10 folds (see 
below), to obtain an overall performance figure for the current choice of inducer 
.   
 
The above performance values for the four choices (SVM, RF, WV and NB) of 
inducer  were then compared, leading to a permanent selection of inducer 
.  Note that although different feature selections and feature numbers were used 
to obtain the final choice , so far these were only tried within nested LOOCV 
within each fold.  At this point, an overall final choice of  and  for the entire 
training set was made, contingent on the now final choice of  (see pseudocode 
in Figure 10).  This was done by taking the entire training set  and performing a 
global LOOCV on it, one for each choice of .  The best performing choice 
from these combinations (again denoted as ) was selected to be the value 
for .  
 
With the now-fixed choice of inducer, gene selection method and number of 
features , we needed to choose the  genes themselves to use as the 
final feature set for the final classifier.  This was done by tracing the  most 
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frequently selected genes in the above global LOOCV, using the above selected 
choice of .  The final classifier was built on the full training set using the inducer 
 and the final feature set.   
 
 
The dataset  consists of the data collection , with each  consisting of 
a feature vector of gene expressions.  That is, , with  denoting the 
expression of gene  in subject , while  denotes the class of the patient (  denotes 
cancer and  denotes no cancer). 
 
Define the set of inducers: , (i.e.,  denotes one of these choices) where:  
 = weighted voting 
 = -  (support vector machine with recursive feature elimination) 
 = random forest 
 = naïve Bayes. 
 
Define the set of gene selection methods: , where:  
 is the gene selection method using the following protocol: 
A Welch t-test between the cancer and control groups is performed for each gene, which 
generates a  value for each gene. The  genes with the highest magnitude  values are 
selected, where  is a pre-defined integer value. 
is the gene selection method using the following protocol: 
A Welch t-test between the cancer and control groups is performed for each gene, which 
generates a  value for each gene. The genes with the  highest  values and  
lowest (most negative)  values are selected, where  is a pre-defined integer value.  
Note that positive  values represent up-regulation of the gene in the case (cancer) 
subjects, while negative  values represent up-regulation of the gene in the control (non-
cancer) subjects. 
 
Define the set of integer values for numbers of genes to select:  
 
 
 
Figure 8: Definitions for the Data Set, Inducers, Gene Selection Methods, 
and Number of Genes to Select 
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Procedure for choosing the optimal inducer, , by nested cross validation: 
Require:  (an inducer where  (a gene selection method where 
),  (a fixed collection of integer values, between 2 and 1,000, for numbers of 
genes to select),  (a training set) 
1. for each inducer a: 
2.      Split  into  folds, , where  
3.      for each fold   
4.           Select the optimal gene selection parameters,  using LOOCV within 
 only, which denotes the 90% of samples outside of  (see Notes)  
5.           Train model (using current inducer , and the now optimized pair )  on  
6.           Test model on  and calculate AUCa( ) 
7.      end for 
8.       = ) 
9. end for 
10. Determine the optimal inducer ,given by  
 
 
Figure 9: Procedure for Choosing the Optimal Inducer by Nested Cross 
Validation 
NOTES:  In Step 4, all pairs  of gene selection methods  (including both methods) and 
feature numbers  (ranging over the abovementioned values between 2 and 1,000) were tried 
using a nested LOOCV within the current training set  (see Figure 10: Procedure for Choosing 
the Optimal Gene Selection Parameters Using Leave-One-Out Cross Validation). 
 
  
61 
 
 
 
Procedure for choosing the optimal gene selection parameters ( , ) by LOOCV: 
Require:  (an inducer where  (a gene selection method where 
),  (a fixed collection of integer values, between 2 and 1,000, for numbers of 
genes to select),  (a training set) 
1.  for each element  do: 
2.      for each gene selection method , do 
3.          for each value  of predefined numbers of genes to select do 
4.                Train classifier on (i.e.,  without ) using the following parameter values: 
gene selection method , predefined number of genes to select , and inducer  
5.                Test classifier on generating a prediction score, for ,  
6.           end for 
7.      end for 
8. end for 
9. for each pair of values calculate an  from the leave-one-out cross validation, 
, by merging the scores and class labels  across all left-out 
samples, , producing the set of scores and class labels  
10. Determine the optimal pair  given by    =  
 
 
Figure 10: Procedure for Choosing the Optimal Gene Selection Parameters 
by Leave-One-Out Cross Validation 
Notes:  The above procedure for LOOCV determination of  and  is first executed as a part of 
determining the optimal inducer  (see Figure 9, in which case  refers to each training fold of the 
above 10-fold cross-validation).  Once the optimal inducer  is fixed, the above procedure is 
executed again in order to make the final determination of  and  (in which case  refers to the 
full training set).   
 
3.3.9 Biomarker Selection Results: Choosing a 5-Gene, Weighted Voting 
Biomarker 
The nested cross-validation procedure for selecting the optimal inducer (see 
pseudocode in Figure 9) generated average AUC values for each inducer (see 
Table 12).  The inducer with the highest average AUC in nested cross validation 
was weighted voting (WV), having an AUC value of 0.74, so that WV was chosen 
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as the final inducer for the full training set.  This completed the first stage of the 
machine selection, with the choice of optimal inducer  WV.  The second 
stage consisted of determining the final gene selection method  and the value  
for number of genes to be selected, this time based on LOOCV using the full 
training set and fixed  WV.  The LOOCV AUC values for each pair  are 
plotted in Figure 11.  The parameters that maximized LOOCV AUC were  
 (the highest magnitude  statistic method), and  5 (the number of 
genes to be used in the selected feature set). 
 
With the now-fixed choices of inducer, gene selection method and number of 
features  , the most frequently selected 
genes from the LOOCV were used as the feature set for the final classifier, to be 
validated on the full test set.  Using this feature set of 5 genes, the classifier to be 
validated was trained on the full training set using .  Note that this 5-gene 
classifier is a scoring classifier, i.e., one assigning a score to each sample 
representing the degree of conviction of the machine regarding the likelihood of 
cancer in the subject.  We note that the score is uncalibrated, i.e. not normalized 
to be a probability.  This 5-gene classifier was then applied to datasets that were 
independent from the training data, as described in the next section. 
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Table 12: Nested Cross Validation Results on the Training Set for Each 
Inducer 
Classifier Average AUC 
Weighted Voting 0.74 
Naïve Bayes 0.69 
Random Forest 0.67 
SVM-RFE 0.67 
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Figure 11: Tuning of Feature Selection Parameters for the Weighted Voting 
Inducer 
Leave-one-out cross validation results on the training set.  The x-axis displays the number of 
genes selected transformed by taking the logarithm in base 2 (see Figure 8 for list of values for 
numbers of genes to select, ranging from 2 to 1,000 genes).  The y-axis displays the AUC, and 
the points are colored according to the gene selection method used ( or , see Figure 8 for 
definitions).  The performance of the weighted voting inducer was maximized by the choice of 
 for the gene selection method and 5 for the number of genes. 
 
3.3.10 Validation of the 5-Gene Biomarker 
The 5-gene weighted voting biomarker was tested on three independent data 
sets: 1) the test set (n = 33, 23 cancer subjects and 10 control subjects), 2) the 
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validation set (  50, 41 cancer subjects and 9 control subjects), and 3) the 
combined set, being the combination of samples in the test set and validation set 
(n=83, 64 cancer subjects and 19 control subjects).  Note that the test set 
samples were processed together with the training set samples, whereas the 
validation set samples were processed separately.  The AUCs for the test set, 
validation set, and combined set were 0.674, 0.74, and 0.682, respectively, and 
the corresponding ROC curves are shown in Figure 12. 
 
We used the Wilcoxon rank-sum test to determine whether the 5-gene classifier 
assigned statistically higher scores to cancer subjects than control subjects (as it 
was trained), or assigned the same distribution of scores to subjects from both 
classes.  The Wilcoxon rank-sum test P-values for the test set (n = 33), validation 
set (n = 50), and combined set (n = 84) were 0.12, 1.6e-07, and 1.2e-06, 
respectively.  Therefore, the 5-gene weighted voting biomarker assigned higher 
scores to cancer subjects than control subjects in the validation set and 
combined set, but not the test set.  The negative result in the test set may be 
largely due to the fact that this dataset had the smallest sample size (n = 33). 
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Figure 12: ROC Curves for the 5-Gene Biomarker in the Test Set, Validation 
Set, and Combined Set 
A) Test Set (n = 33, 23 cancer and 10 control), B) Validation Set (n = 50, 41 cancer and 9 
control), C) Combined Set (n = 83, 64 cancer and 19 control) 
 
3.3.11 Clinico-Genomic Classifier Development 
In order for the gene expression biomarker to be clinically useful, it would have to 
be predictive of lung cancer independently of currently used clinical risk factors 
and CT scans.  Therefore, we sought to determine whether the gene expression 
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biomarker is independently associated with lung cancer when clinical factors are 
also incorporated into a combined clinico-genomic model.  As an initial 
assessment using the training set, we combined mass sizes recorded from 
radiography scans and biomarker scores generated by the 5-gene biomarker into 
a logistic regression model.  Mass size was coded as “0” for a mass that is less 
than 3 cm across, “1” for a mass that was greater than 3 cm across, and “NA” for 
missing data.  Biomarker score was significantly associated with lung cancer 
independently from mass size, p < 0.001.  After comparing the performance of 
logistic regression and naïve Bayes on the training set, naïve Bayes was chosen 
for validation.  The performance of the naïve Bayes clinico-genomic classifier on 
the test set, validation set, and combined set are shown in Figure 13.  The 
clinico-genomic classifier outperforms the clinical model in the combined set 
(AUC = 0.738 vs 0.692) but the difference is not statistically significant (P = 0.26). 
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3.3.12 Clinico-Genomic Prediction Model Results 
 
 
Figure 13: ROC Curves for the Clinico-Genomic Classifier in the Test Set, 
Validation Set, and Combined Set 
A) Test Set (n = 33, 23 cancer and 10 control), B) Validation Set (n = 50, 41 cancer and 9 
control), C) Combined Set (n = 83, 64 cancer and 19 control) 
 
3.4 Discussion 
 
Within our study population of subjects undergoing clinical evaluation for 
suspicion of lung cancer, we have identified lung-cancer associated gene 
expression in nasal epithelial cells.  We have summarized the lung-cancer 
associated nasal gene expression as a 194 gene signature and established that 
this signature is also enriched in bronchial epithelial cells indicating that there is a 
common, cancer-associated, airway-wide gene expression response.  
Furthermore, we have developed a scoring classifier which uses as input the 
expression of only 5 genes, and outputs a numerical score that is higher in lung 
cancer patients than patients with non-cancer pathologies (n = 83 test samples, 
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consisting of 64 cancer subjects and 19 control subjects, Wilcoxon rank-sum test 
P-value = 1.2e-6).  
 
There is a pressing need for additional methods for lung cancer screening in 
high-risk smokers.  Obtaining nasal epithelial cells by brushing is minimally 
invasive therefore it could be applied as a screening tool.  The National Lung 
Screening Trial (NLST) has shown that serial, yearly CT scans in high-risk 
smokers decreases lung cancer mortality (Aberle et al., 2011).  However, the 
screening method used in the study is impractical for general adoption given the 
high number of false positives (over 20% of subjects had a CT-detected lesion 
and were sent for additional follow-up, but 96% of these subjects did not have 
lung cancer).  The addition of a minimally invasive, molecular biomarker tool may 
improve accuracy of diagnosis over CT screening alone. 
 
The presence of lung cancer-associated gene expression in nasal epithelium is 
consistent with the cancer field effect phenomenon, where histologically normal 
epithelial cells in the region adjacent to a neoplasm also exhibit molecular 
abnormalities (see review by Steiling et al., 2008).  The mechanism responsible 
for lung-cancer-associated, nasal gene expression is currently unknown but we 
can draw hypotheses from the existing literature on field cancerization and the 
smoking field of injury (Gomperts et al., 2011; Gower et al., 2011; Gustafson et 
al., 2010; Hanahan and Weinberg, 2011; Steiling et al., 2008).  The lung cancer-
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associated, nasal gene expression may be due to one or more of the following, 
1) a response to the presence of the tumor, 2) cigarette smoke-induced damage 
to the airway that increases risk for carcinogenesis, and/or 3) physiological 
processes occurring in control subjects, whose diagnoses include tuberculosis, 
pneumonia, and sarcoidosis.  These hypotheses may be tested in the future by 
profiling nasal gene expression in the following cohorts, 1) lung cancer patients 
before and after lung tumor resection, 2) never, current, and former smokers, and 
3) larger groups of subjects with tuberculosis, pneumonia and sarcoidosis. 
 
The phenomenon of lung-cancer-associated nasal gene expression is surprising 
for several reasons.  First, the nasal turbinate is a relatively long distance from 
the lung tumor.  Second, although both the nasal epithelium and bronchial 
epithelium are exposed to cigarette smoke, carcinomas occur commonly in the 
lungs but rarely in the nose, although smoking is a risk factor for nasal carcinoma 
(Greiser et al., 2012).  However, this phenomenon is consistent with previous 
observations.  The nasal epithelium and bronchial epithelium are connected by 
the respiratory tract and have shared biology, function, and environment (Caimmi 
et al., 2012; Harkema et al., 2006; Krouse, 2008).  It has also been shown that 
nasal epithelial cell gene expression and bronchial epithelial cell gene expression 
are affected similarly by tobacco smoke exposure (Sridhar et al., 2008; Zhang et 
al., 2010). 
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Although nasal carcinomas are rare, the genes with increased expression in the 
cancer group are enriched in GO terms and KEGG pathways consistent with 
carcinoma development.  Most strikingly, the KEGG pathways “basal cell 
carcinoma” and “hedgehog signaling pathway” are both enriched at FDR q-value 
< 0.05.  This is likely to be a true positive because, like lung carcinomas, basal 
cell carcinomas are also epithelial cancers (though typically caused by different 
external, mutagenic factors: cigarette smoke vs UV exposure, respectively).  
Enriched GO terms include cell adhesion and morphogenesis, which are also 
associated with cancer. 
 
The genes with increased gene expression in the control group are enriched in 
GO terms and KEGG pathways mainly related to immune response.  This result 
is consistent with the fact that most subjects in the control group have non-
cancer pathologies that involve immune responses (e.g. tuberculosis, 
sarcoidosis, and pneumonia).  It has been shown previously that nasal gene 
expression can distinguish between acute and chronic asthma and our data 
suggest that nasal gene expression also reflects the presence of other 
pulmonary diseases (Guajardo et al., 2005; Lopez-Guisa et al., 2012).  If given a 
larger sample size, it may be possible to identify nasal gene expression 
signatures that are specific to individual pulmonary diseases that are present in 
the control subjects. 
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The 5-gene biomarker was selected from the training set based on AUC 
maximization.  AUC was chosen as the performance metric for three reasons.  
First, our goal was to create a classifier that outputs a score (as opposed to a 
binary classification) and therefore the relevant test was whether or not the 
scores given to cancer cases were higher than those given to controls.  Second, 
AUC describes the classifier performance across a range of threshold values.  
Third, AUC takes into account performance on cancer cases and controls 
equally.  A common criticism of biomarker selection based on AUC is that the 
biomarker performance on clinical test samples is only based on the binary 
classification created when a specific threshold is applied.  However, 
thresholding is not done for a scoring classifier.  Our choice of developing a 
scoring classifier was partly based on the success of Oncotype DX, which is a 
gene expression biomarker used to predict breast cancer recurrence based on 
tumor samples. 
 
Depending on the nature of the lung cancer-associated nasal gene expression 
signature, the signature may meet clinical needs beyond diagnosis.  One 
application may be monitoring patients for lung cancer recurrence.  If the 
signature is a response to the presence of the tumor, complete tumor resection 
would presumably cause the signature to subside and cancer recurrence would 
then cause the signature to reappear.  Another application would be lung cancer 
risk assessment/pre-screening.  If the signature precedes the development of 
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lung cancer, i.e. is a biomarker for lung cancer risk, it could be used to identify 
patients who would benefit from additional screening or chemoprevention--the 
use of medicines or dietary supplements to prevent cancer development.  Our 
group has previously reported a bronchial biomarker for both detection of lung 
cancer risk and the response to therapy (Gustafson et al. 2010) Administration of 
myoinositol to smokers with dysplastic (precancerous) lesions caused significant 
regression of lesions and reversal of PI3K pathway activation.   
 
A key question was whether the clinico-genomic biomarker could outperform the 
current clinical prediction model.  Ideally, in our analysis we would have used a 
clinical model that contains smoking history, age, etc.  We chose to use CT 
acquired mass size alone, which is not the complete model, but it is the strongest 
single predictor.  Importantly, a logistic regression model that combined mass 
size and biomarker score in the training set showed that the biomarker score is a 
significant predictor of lung cancer status independently from mass size.  This 
independence suggests that the biomarker would be clinically useful as it gives 
diagnostic information that is not obtained by CT scan (it also suggests that nasal 
profiling could improve screening in combination with CT scan).  The clinico-
genomic biomarker outperformed the clinical prediction on the combined test and 
validation sets (AUC 0.738 vs. 0.692), although the difference was not 
statistically significant (P = 0.26).    
 
74 
 
In conclusion, we have discovered that there is a common, lung cancer-
associated gene expression signature in the nasal epithelium and throughout the 
human airway.  We have developed a simple 5-gene biomarker and have 
validated it on independent test sets (P < 0.001, n = 83, 64 cancer and 19 control 
subjects).  Although the AUC is too low for current clinical use (0.68), our results 
strongly suggest that this nasal gene expression could be used for lung cancer 
diagnosis in the future.  Given that nasal sample collection is inexpensive and 
noninvasive, future work should investigate its use as a molecular screening tool 
that may complement CT-screening. 
 
3.5 Methods 
 
3.5.1 Experimental Protocol for Microarray Processing 
All procedures were performed at Boston University Microarray Resource 
Facility.  The total RNA (100-200 ng) was reverse-transcribed using Ambion® 
WT Expression Kit (Life Technologies).  The obtained cDNA was used as a 
template for in vitro transcription using Ambion® WT Expression Kit (Life 
Technologies).  The obtained antisense cRNA was purified using Nucleic Acid 
Binding Beads (Ambion® WT Expression Kit, Life Technologies), and then used 
as a template for reverse transcription to produce single-stranded DNA in the 
sense orientation.  During this step dUTP was incorporated.  The DNA was then 
fragmented using uracil DNA glycosylase (UDG) and apurinic/apyrimidinic 
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endonuclease 1 (APE 1) and labeled with DNA Labeling Reagent that is 
covalently linked to biotin using terminal deoxynucleotidyl transferase (TdT, 
Whole Transcript Terminal Labeling and Controls kit, Affymetrix, Santa Clara, 
CA).  IVT and cDNA fragmentation quality controls were carried out by running 
an mRNA Nano assay in the Agilent 2100 Bioanalyzer. 
 
The labeled fragmented DNA was hybridized to the Gene Arrays 1.0ST.  
Microarrays were immediately scanned using Affymetrix GeneArray Scanner 
3000 7G Plus (Affymetrix, Santa Clara, CA).  
 
3.5.2 Quality Control Filer for Microarray Data 
Due to low RNA quality across samples in the nasal data sets (defined for each 
sample by the RNA Integrity Number (RIN) produced by the Agilent Bioanalyzer 
2100), data from a number of microarrays failed standard quality control metrics.  
Microarray quality filters were developed on dataset 2, which contains the 
training and test sets, and the same filters and cutoffs were applied to dataset 1, 
which contains the validation set.  Out of 200 microarrays that were run in 
dataset 2 (containing the training and test sets), 29 microarrays were filtered out 
based on standard quality control metrics, specifically Positive vs. Negative AUC, 
RLE, and NUSE.  First, arrays were filtered using Positive vs. Negative AUC <= 
0.8 as calculated by Affymetrix Expression Console software on Windows.  Next, 
RLE and NUSE were computed for arrays that passed the Positive vs. Negative 
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AUC filter.  Arrays with NUSE > 1.02 or RLE > 0.1 were excluded from analysis.  
The same data quality control procedure and thresholds applied to dataset 2 
were applied to dataset 1.  Out of 107 microarrays in dataset 2, 28 were filtered 
out. 
 
3.5.3 Generation of Gene Expression Values 
Expression values were generated using Robust multi-chip average (Bolstad et 
al., 2003; Irizarry et al., 2003a; Irizarry et al., 2003b) with BrainArray CDF version 
14.1 (Dai et al., 2005) run on R-2.12.2 using the bioconductor / affy package? 
 
3.5.4 Differential Expression Analysis 
Using only the training set, differentially expressed genes with respect to cancer 
status were identified by Welch t-test.  The 194 genes with P value < 0.005 were 
considered differentially expressed. 
 
3.5.5 Gene Set Enrichment Analysis  
The GSEA v. 2.0 Java application was used for GSEA analysis. 
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4. An Ensemble Biomarker for Lung Cancer Early Detection Using Nasal 
Epithelial Gene Expression 
 
4.1 Introduction 
 
An ensemble classifier is a combination of individual classifiers that is designed 
to surpass the performance of all of the individual classifiers (termed “base 
classifiers”).  Ensemble classifiers have been shown to be successful in a 
number of applications, including cancer classification using gene expression 
data (Breiman, 2001; Cornero et al., 2012; Datta et al., 2010; Rokach et al., 
2013).  We previously developed a 5-gene biomarker that achieved reasonable 
performance on independent samples (see Chapter 3).  In this chapter, we 
explore the development of ensemble classifiers and evaluate their performance 
on the same datasets used to train and validate the 5-gene biomarker. 
 
4.2 Background 
 
In this section we will describe the protocol used to develop the ensemble 
classifier for lung cancer diagnosis based on nasal gene expression 
measurements.  We took data in the form of nasal gene expression, and built a 
learning machine that trained on a portion of the dataset (the training set), and 
was then tested on the remaining portion (the test set and validation set).  The 
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goal was to demonstrate that such a machine could be built to accurately 
diagnose lung cancer in the field, based on its performance on our test data set. 
 
Ensemble classifiers have two components: individual classifiers (called base 
classifiers) and voting schemes.  These voting schemes take the predictions from 
all of the base classifiers and transform them into a single, final prediction (the 
ensemble prediction).  In a voting scheme (e.g. majority voting or weighted 
voting), each base classifier is given a vote.  In majority voting, the ensemble 
prediction is simply the prediction given by the majority of base classifiers.  In 
weighted voting, the votes are weighted according to the performance of the 
respective base classifiers, so that the predictions of the best performing base 
classifiers are given the highest weights.  We have also explored a more 
sophisticated type of voting scheme, called stacking (also known as stacked 
generalization).  In stacking, the outputs of the base classifiers are treated as 
new variables (i.e. features) that form a new classification problem.  Together 
with the original class labels, these new variables form a new set of training data 
(the meta-level training set).  The meta-level training set is given to a learning 
algorithm to create a meta-classifier, and the meta-classifier gives the ensemble 
prediction.  Any type of learning algorithm can be used to construct the meta-
classifier, due to the general nature of the new classification problem.  In addition 
to exploring the stacking method using all base classifiers, we tried stacking 
using only the top-performing base classifiers.  We compared the three methods 
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we have outlined above (voting, stacking with all base classifiers, and stacking 
with a top-performing subset of base classifiers).  And then chose the best 
performing ensemble classifier for validation.  We trained the ensemble classifier 
using the same training set (n = 97, 68 cancer subjects and 29 control subjects) 
used for the 5-gene biomarker.  We tested the ensemble classifier on the same 
three independent datasets as the 5-gene biomarker: 1) the test set (n = 33, 23 
cancer subjects and 10 control subjects), 2) the validation set (n = 50, 41 cancer 
subjects and 9 control subjects), and 3) the combined set, being the combination 
of samples in the test set and validation set (n = 83, 64 cancer subjects and 19 
control subjects). The demographics tables for these datasets can be found in 
Chapter 3 (Tables 4-7). 
 
We began by constructing and testing a set of base classifiers in the context of 
leave-one-out cross validation on the training set.  We used the following 
procedure, using the terminology of Wei Fan et al. (Wei Fan, 1999).  We denote 
our training set, , where each  denotes a feature 
vector of gene expression values for subject  while   denotes the class of the 
 subject (  denotes cancer and  denotes control).   was 
partitioned into  parts for leave-one-out cross validation.  A single sample left 
out from  is annotated  and contains the data and class label .  The set 
of remaining samples left within  is annotated . The number of (base) 
learning algorithms used to produce the base classifiers is , and these learning 
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algorithms are denoted as .  For each sample left out during LOOCV, 
algorithms  were trained on  to produce base classifiers  to (note 
that the first index denotes the base classifier and the second index denotes the 
sample left out).  Next, the base classifiers  to  were used to generate 
predictions on the left out sample,  with the base classifier predictions for 
denoted as .  These form a vector of base classifier 
predictions,  for the  sample.  In order to derive the ensemble prediction for 
the sample, the vector of base classifier predictions, , were acted upon by 
either a voting scheme or meta-classifier. In the meta-classifier case, we defined 
a new meta-level training set, , where each  
denotes a feature vector of base classifier scores for subject  while  denotes 
the class of the  subject.  Using , we constructed and compared the 
performance of meta-classifiers using three different algorithms: NB (naïve 
Bayes), WV (the weighted voting algorithm in Golub et al. 1999, not to be 
confused with the voting scheme by the same name), and RF (random forest). 
 
4.3 Results 
 
For the ensembles that used voting schemes, weighted voting performed best, 
having an accuracy of 0.639 (Table 13).  For the ensembles that used meta-
classifiers, the random forest meta-classifier using all 102 base classifiers 
performed best, having an AUC of 0.745 (Table 14).  Within the meta-
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classification scheme, we tested the hypothesis that discarding the poorest 
performing base classifiers would improve ensemble classifier performance.  We 
performed rank-based selection of the top q base classifiers and built meta-
classifiers using only those base classifiers that ranked within the top q (
   The base classifiers were ranked 
based on how well their cancer likelihood scores separated cancer from control 
subjects (using  P-values derived from Welch t-tests comparing the scores given 
to the cancer and control subjects).  For each value of q, the top  base 
classifiers were incorporated into meta-classifiers built by random forest, naïve 
Bayes, or weighted voting.  The training set leave-one-out cross validation results 
for these meta-classifiers are shown in Table 15. 
 
As shown in Table 15, using a subset of top-performing base classifiers did not 
improve performance over using all 102 base classifiers.  The top performing 
ensemble classifier remained the random forest meta-classifier that incorporated 
all 102 base classifiers.  The top four ensemble classifiers were all random forest 
meta-classifiers incorporating a large number of base classifiers.  Naïve Bayes 
and weighted voting meta-classifiers generally performed worse than the random 
forest meta-classifiers. 
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Table 13: Leave-One-Out Cross Validation Performance of Ensemble 
Classifiers Using Voting Schemes 
Both majority vote and weighted vote methods used the leave-one-out cross validation 
predictions from all base classifiers as input.  For the weighted vote combiner, base classifier 
predictions were weighted by the leave-one-out cross validation AUC values for the base 
classifiers. 
Combiner ACC SENS SPEC AVG(SENS+SPEC) 
Majority vote 0.639 0.721 0.448 0.58 
Weighted vote 0.629 0.632 0.621 0.627 
 
 
Table 14: Leave-One-Out Cross Validation Performance of Ensemble 
Classifiers Using Meta-Classification 
The meta-classifiers listed in this table used the leave-one-out cross validation confidence scores 
from all base classifiers as input. 
Combiner AUC 
Random forest  
meta-classifier 0.745 
Weighted voting  
meta-classifier  0.619 
Naïve Bayes  
meta-classifier 0.597 
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Table 15: Leave-One-Out Cross Validation Performance of Meta-Classifiers 
Incorporating Between 2 and 102 Base Classifiers 
Number of base 
classifiers 
Combiner 
(meta-classifier) 
AUC 
Rank 
(by AUC) 
102 random forest 0.745 1 
100 random forest 0.745 2 
40 random forest 0.714 3 
80 random forest 0.713 4 
2 weighted voting 0.706 5 
60 random forest 0.699 6 
6 random forest 0.691 7 
30 random forest 0.688 8 
2 random forest 0.687 9 
5 random forest 0.677 10 
7 naïve Bayes 0.67 11 
4 weighted voting 0.668 12 
4 random forest 0.668 13 
5 weighted voting 0.665 14 
3 random forest 0.662 15 
3 weighted voting 0.661 16 
8 random forest 0.656 17 
2 naïve Bayes 0.655 18 
15 random forest 0.651 19 
5 naïve Bayes 0.651 20 
9 random forest 0.65 21 
7 random forest 0.648 22 
6 naïve Bayes 0.647 23 
8 naïve Bayes 0.642 24 
20 random forest 0.642 25 
20 weighted voting 0.641 26 
4 naïve Bayes 0.636 27 
10 random forest 0.636 28 
40 weighted voting 0.633 29 
7 weighted voting 0.63 30 
15 naïve Bayes 0.629 31 
6 weighted voting 0.627 32 
9 naïve Bayes 0.626 33 
10 naïve Bayes 0.626 34 
30 weighted voting 0.626 35 
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Number of base 
classifiers 
Combiner 
(meta-classifier) 
AUC 
Rank 
(by AUC) 
60 weighted voting 0.624 36 
40 naïve Bayes 0.623 37 
15 weighted voting 0.62 38 
102 weighted voting 0.619 39 
80 weighted voting 0.619 40 
100 weighted voting 0.619 41 
3 naïve Bayes 0.616 42 
20 naïve Bayes 0.613 43 
30 naïve Bayes 0.613 44 
60 naïve Bayes 0.607 45 
80 naïve Bayes 0.6 46 
102 naïve Bayes 0.597 47 
100 naïve Bayes 0.597 48 
8 weighted voting 0.561 49 
10 weighted voting 0.525 50 
9 weighted voting 0.511 51 
 
 
The random forest meta-classifier incorporating all 102 base classifiers 
maximized AUC on the training set and therefore was selected for validation.  
The random forest meta-classifier performance on the test set (n = 33), validation 
set (n = 50), and combined set (n = 83) are shown below in Figure 14. 
 
To better evaluate performance of the classifier on independent samples, the test 
and validation sets were combined, creating a single dataset with a larger sample 
size.  Since the test and validation sets were generated at different times, when 
they were later combined they were adjusted for technical differences using 
ComBat, a microarray normalization tool for reducing batch effects (Johnson et 
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al., 2007).  The random forest meta-classifier was then tested on the combined 
and normalized test and validation sets, and achieved an AUC of 0.687.  The 
performance of the random forest meta-classifier was approximately equal to the 
performance of the 5-gene classifier described in Chapter 3, which achieved 
areas under the curve of 0.67, 0.74, and 0.684 for the test set, validation set, and 
combined set, respectively.   
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Figure 14: ROC Curves for the Random Forest Ensemble Classifier in the 
Test Set, Validation Set, and Combined Set 
A) Test Set (n = 33, 23 cancer and 10 control), B) Validation Set (n = 50, 41 cancer and 9 
control), C) Combined Set (n = 83, 64 cancer and 19 control) 
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4.4 Discussion 
 
It has previously been shown that ensemble classifiers can outperform individual 
classifiers (Rokach et al., 2013).  Here, we have constructed multiple types of 
ensemble classifiers in an attempt to improve on an existing 5-gene nasal gene 
expression biomarker for lung cancer diagnosis (see Chapter 3).  The original 5-
gene biomarker achieved areas under the curve of 0.67, 0.74, and 0.684 on the 
test, validation, and combined (test and validation) sets, respectively.  We have 
now constructed an ensemble classifier that matches, but does not exceed, the 
performance of the 5-gene biomarker. 
 
The 5-gene, nasal gene expression biomarker was selected out of 102 
combinations of inducers, gene selection methods, and numbers of genes.  The 
same 102 methods have been used here to generate base classifiers that were 
then combined into different types of ensemble classifiers using different 
combiners, namely majority vote, weighted vote, sum of weighted scores, and 
meta-classification (stacking).  The best-performing ensemble combiner on the 
training set was a random forest meta-classifier that incorporated all 102 base 
classifiers.  The areas under the curve for the ensemble classifier on the test, 
validation, and combined sets were 0.65, 0.75, and 0.687 respectively.  
Therefore, the random forest meta-classifier performed about equally as well as 
the original 5-gene classifier and we have failed to identify a meta-classifier that 
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could outperform the original biomarker.  We recall as previously stated that this 
best performing combiner arose from several different ones that were tried on the 
training set, but that this was the only combiner that was tried on the test set. 
 
Both the majority vote and weighted vote ensemble classifiers performed poorly 
on the training set.  These are simple combination rules and were naturally the 
first ensemble methods to try.  They may have failed, in part, because they do 
not use learning on the meta-level.  Another reason for poor performance may be 
the use of base classifier binary predictions as opposed to likelihood scores.  The 
base classifier predictions are produced internally by applying thresholds to the 
likelihood scores and the thresholds may be sub-optimal.  Importantly, the 
weighted vote meta-classifier outperformed the majority vote meta-classifier.  As 
expected, weighting the votes by the performance of the base classifiers did 
improve the performance of the ensemble.  
 
One of our hypotheses was that ensemble classifiers that used the base 
classifier score (likelihood of cancer) as input would outperform those that used 
the base classifier binary predictions (cancer vs. no cancer) as input.  This 
hypothesis was based on the fact that information is lost when the likelihoods are 
converted into predictions internally by the base classifiers.  This hypothesis was 
validated on the training set where the meta-classifiers using the scores 
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outperformed the majority vote and weighted vote ensemble methods, which 
used the binary predictions.   
 
One hypothesis that did not validate was that selecting a subset of top-
performing base classifiers would lead to a better ensemble than including all 
base classifiers.  Three different types of meta-classifiers (random forest, naïve 
Bayes, and weighted voting) were compared with different subsets of base 
classifiers.  Surprisingly, including all base classifiers in a random forest meta-
classifier resulted in better performance than was achieved in all other meta-
classifiers on the training set.  Random forest even showed a performance gain 
when adding the worst-performing base classifiers.  Interestingly, selecting a 
subset of top-performing base classifiers did improve the performance of naïve 
Bayes and weighted voting meta-classifiers.  It may be that the embedded, 
automatic classifier selection within the random forest meta-classifier enabled it 
to outperform the naïve Bayes and weighted voting meta-classifiers. 
 
One criticism of this analysis may be that the base classifiers lack diversity.  
There are a number of other classification methods that could have been applied 
here.  We have created base classifiers using the existing framework (inducers, 
gene selection methods, and numbers of genes) from the development of the 
original 5 gene biomarker as opposed to starting over with entirely different 
classification techniques.  In our opinion it is unlikely that the incorporation of 
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additional classification methods would have improved ensemble classifier 
performance.  Although only four base inducers were used here (SVM-RFE, 
random forest, naïve Bayes, and weighted voting), these inducers are fairly 
diverse and include multiple embedded feature selection methods. 
 
4.5 Methods 
 
All analysis was performed using the biomarker pipeline that is described in 
Chapter 5. 
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5. R Package and Batch Submission Pipeline for Biomarker Development 
and Validation 
 
5.1 Introduction 
 
The central challenge to Aim 2, developing a nasal biomarker for lung cancer, 
was building and selecting the best classifier using the training set data.  Several 
authors have compared the performance of multiple classification algorithms 
across multiple data sets and shown that no classification algorithm outperforms 
the others across all data sets (Hu, 2006; Potter, 2007).  Therefore, in order to 
identify the best classifier for this nasal data set, it was important to compare 
different classifiers on the training set before selecting the final classifier to 
validate.   
 
There are a number of software packages for comparing multiple types of 
classifiers using cross validation, e.g. WEKA (Hall M., 2009) and RWEKA (Hornik 
et al., 2013), The Spider (http://people.kyb.tuebingen.mpg.de/spider/main.html), 
and CMA (Slawski et al., 2008).  However none of these packages had either the 
combination of algorithms or the R platform implementation that was necessary 
for our planned analysis. 
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There were a number of challenges that appeared during the development of the 
nasal biomarker, each of which was addressed with a different software package 
feature.  One issue was the small number of samples in the training set.  This 
was addressed by leave-one-out cross validation, which uses the maximum 
number of samples on which to train, minimizing bias.  Another problem was that 
in sets with a large unbalance in the number of cancer and control cases, there 
tended to be prediction bias toward the overrepresented class which confounded 
the results.  This was avoided by using oversampling of the minority class within 
cross validation, in which the underrepresented class was oversampled 
(duplicated) to create a balanced set.  One challenge involved cancer-associated 
genes that happen to be X-linked, and therefore results were confounded with 
gender.  In this case, employment of gene selection using linear models allowed 
selection of genes while avoiding confounding.  Another tool, nested cross 
validation, was used to estimate test set performance and generated a better 
performance estimate than standard cross validation.  This was because the 
nested cross validation takes into account overfitting that can be caused by 
selecting the top performing model over a large number of weaker performing 
models.  Also, since ensemble classifiers often outperform single classifiers, 
adding the ensemble classification feature to the software package added to its 
functionality. 
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In order to construct a software package with all of these features, we modified 
the Bioconductor package, Classification for Microarrays (CMA) (Slawski et al., 
2008) to create an improved package that we named the CMA* package.  We 
also created a pipeline to greatly reduce computation time by parallelizing jobs 
on a compute cluster, running Sun Grid Engine (SGE), that we named CMA* 
pipeline.  The resulting R package and SGE pipeline have the full functionality 
mentioned above.  In addition, they are fast, easy to use, and give reproducible 
results.  Unlike CMA, CMA* also allows the user to specify training and test sets 
for biomarker validation. 
 
5.2 Background 
 
5.2.1 Comparison of Packages That Can be Used to Compare Multiple 
Classification Algorithms on User Data 
There are a number of open-source software packages that can be used to 
compare the performance of multiple classification algorithms.  These include 
WEKA (Hall M., 2009) and its R interface, RWEKA (Hornik et al., 2013), the 
Spider (http://people.kyb.tuebingen.mpg.de/spider/main.html), and CMA (Slawski 
et al., 2008).  WEKA is available as a Java-based GUI and open-source Java 
code, while RWEKA is an R interface to WEKA with a reduced set of WEKA 
features, the Spider is a Matlab package, and CMA is an R package.   
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By far, the most full-featured and most cited tool for comparing multiple 
classification techniques is WEKA.  WEKA has a large number of feature 
selection and classification algorithms and is available as open-source Java 
code.   For those unable to program in Java, there is a version of WEKA that can 
be run on a personal computer. Conveniently, this version of WEKA contains a 
graphical user interface (GUI) and can be run on Windows, Mac, and Linux 
operating systems. However, the analysis described in Chapter 3 has involved 
the repeated execution of a large number of classification algorithms within 
leave-one-out cross validation.  Due to the computationally demanding nature of 
that analysis, the analysis could not have been done using WEKA on a personal 
computer.   
 
The Spider is a freely available Matlab package for comparing multiple 
classification techniques via cross validation.  Its architecture is object-oriented in 
that the classifiers are MatLab objects.  Due to its standardized handling of 
classifiers as objects, it is easy to specify the execution of different types of 
classifiers using a common syntax.  An additional advantage of the Spider is that 
the classification algorithms and cross validation methods can be specified using 
a small number of lines of code.  Although the Spider has several attractive 
features, it has not been updated since 2006 and does not contain newer 
classification methods.  It is mentioned here due the usefulness of its architecture 
as a model for newer software packages to adopt. 
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The Classification for MicroArrays (CMA) is an R package for comparing multiple 
classification techniques via cross validation.  The CMA package has a similar 
architecture to the Spider; CMA is object-oriented and allows for the specification 
of feature selection, classification, and cross validation loops using a small 
number of lines of code.  Unlike the Spider, the CMA package is still supported 
by developers and new versions have become available for download since its 
initial release in 2008.  The CMA package is popular; it has been downloaded 
over 3,000 times in the past year.  Given the modular design of CMA and the 
wealth of freely available R packages with which to enhance it (e.g. packages for 
microarray data normalization, feature selection, and classification), we decided 
to build our new software tools by modifying the CMA package. 
 
5.3 Results 
 
5.3.1 CMA* R Package 
We have modified the CMA package to include new features and have called the 
new software CMA*.  Quality control was performed on the CMA package and a 
major bug was discovered: the predictions were assigned to the incorrect 
samples when using any type of cross validation.  By going into the CMA 
package source code, this bug was fixed.  The CMA* package was then 
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expanded to include additional classification and feature selection methods.  The 
classification methods available in CMA and CMA* are listed in Table 16. 
 
For a given microarray data set, it is often the case that the class label, e.g. 
cancer status, is confounded with another phenotype that is associated with gene 
expression changes, e.g. sex.  However, no feature selection method in CMA 
addressed this type of confounding.  Feature selection by linear model can 
differentiate features that are associated with cancer as opposed to sex by 
including both cancer and sex in a linear model and choosing features that 
associated with cancer independently of sex.  Therefore, we have included linear 
model feature selection in CMA*. 
 
Training sets, especially for disease phenotypes, often have imbalanced class 
ratios that tend to create biased classifiers when using machine learning 
methods, including random forest and SVM.  Random oversampling is one 
strategy for improving classifier performance in this setting.  In random 
oversampling, data instances from the minority class (e.g. data from control 
patients) are randomly selected and replicated to create a new training set, which 
has an equal number of instances from cases and controls.  The new training set 
is then used to train the machine learning algorithm.  Oversampling was not 
included in CMA but we have included it in CMA*. 
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Table 16: Classification Methods Included in CMA* vs. CMA 
Classification Method CMA  CMA* 
Componentwise boosting  
Diagonal discriminant analysis  
Elastic net  
Fisher's discriminant analysis  
Flexible discriminant analysis  
Tree-based boosting   
k-nearest neighbors  
Linear discriminant analysis  
Lasso  
Feed-forward neural networks  
Probalistic nearest neighbors  
Penalized logistic regression  
Partial Least Squares  
Probabilistic neural networks  
Quadratic discriminant analysis  
Random forest  
PAM  
Shrinkage discriminant analysis  
Support vector machines (SVM)  
SVM-RFE  
Top scoring pairs  
Weighted voting  
 
SVM-RFE (SVM with recursive feature elimination), top scoring pairs, and weighted voting are 
included in CMA* in addition to the classification methods that were already in the CMA package. 
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5.3.2 Pipeline That Parallelizes CMA*on a Compute Cluster 
Overview 
The CMA* pipeline submits batch jobs on a compute cluster and vastly speeds 
up biomarker development.  The pipeline also aggregates results into tables and 
visualizations that are saved as small files within a simple directory structure.  
The CMA* pipeline is a collection of scripts for building classifiers to predict 
phenotypes (e.g. cancer, passive smoking) from microarray or RNA-seq data.  
The CMA* pipeline allows the user to do model selection by specifying 
combinations of parameter values (e.g. feature selection method, number of 
features, classification algorithm, variable of interest), submiting jobs on LinGA 
that will cover all combinations of the given parameter values, and recording the 
results for classification performance as well as feature selection.  The pipeline 
has a modular structure and is meant to be expanded over time by users.  The 
CMA* pipeline new features include nested cross validation and ensemble 
biomarker development. 
As input, the pipeline requires class labels in a “SAMPLESHEETFILE” format 
and a data matrix in a “SAMPLEDATAFILE” format (see below for specific 
formatting).  Generating the data matrix before running the CMA* pipeline allows 
the use of any type of data (e.g. microarray, RNA-seq, PCR) and any type of 
preprocessing. 
The CMA* pipeline is located here on LinGA: 
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/protected/projects/pulmarray/biomarker_pipelines/CMA_pipeline/stable/pipeline/ 
 
The CMA* pipeline invokes an enhanced and debugged version of the CMA 
package that was rebuilt from the source code that was modified.  The major bug 
was reported  to the maintainer of the package but it to date, it is unknown if it 
has been fixed.  The Bioconductor page for the CMA package is found here: 
http://www.bioconductor.org/packages/2.3/bioc/html/CMA.html 
Pipeline Requirements 
The CMA* pipeline is currently installed on LinGA, (Linux Clusters for Genetic 
Analysis at Boston University) and LinGA users can run the pipeline without 
needing to install any software.  The CMA* pipeline requires the Sun Grid 
Engine, Linux Bash, Perl, and R-2.12.2.  
CMA* Pipeline Scripts 
The CMA* pipeline consists of 4 main scripts: run_CMA_pipeline.pl, 
user_parameters.pl, CMA_pipeline_core.R, and CMA_pipeline_functions.R. 
The user_parameters.pl is a set of parameters that the user can choose for the 
classifiers they want to build.  The run_CMA_pipeline.pl takes the user 
parameters file (user_parameters.pl) as input and creates the output directories 
(see below), writes the qsub files, and submits the qsub jobs to LinGA.  Kick off 
the CMA* pipeline from the command line by typing: perl run_CMA_pipeline.pl 
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user_parameters.pl.  The command above submits jobs to the queue and 
creates the following directories in the analysis folder specified in the 
user_parameters.pl file. 
 
Output Directories 
reproduction_scripts: contains copies of all of the scripts and the parameter file 
that was used in the analysis.  This ensures that the analysis is reproducible. 
 
qsubs_and_logs: contains the qsub files submitted by the pipeline and the log 
files produced by the qsubs.  These files are helpful for monitoring progress, 
reproducing individual models for investigation, and error checking.  Each qsub 
submits one job to LinGA that passes parameter arguments for a single model to 
CMA_pipeline_core.R. 
 
selected_features: output files that list the selected features for each feature 
selection method and number of features specified (see section "Accessing the 
Results" for more info).   
 
Results: contains files with the cross validation performance and predictions 
made by each model (see section "Accessing the Results" for more info).  This 
folder is generally not needed since the combined results are in the postprocess 
folder. 
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pipeline_core_logs: contains R logs (the equivalent of Rhistory files) that contain 
the output during the R session created by each run of CMA_pipeline_core.R.  
For each model (specified by a single job and a single qsub). 
CMA_pipeline_core.R prints a number of variables to Rout for error checking.  If 
the script completed successfully, the Rout file records the amount of computer 
time used.  If the script did not complete successfully, the Rout file records where 
the script exited.  The name of the Rout file matches the name of the qsub file, 
e.g. 1.Rout matches 1.qsub.  
 
postprocess: postprocess refers to aggregating the results from the CMA* 
pipeline run.  This directory contains files with tables or plots aggregated from 
multiple combinations of parameters.  For example, 
[variable_name]_medians_unique_param_sets.txt contains a table showing the 
classification performance of each unique set of parameters.  
boxplots_[variable_name]_NF.pdf contains box plots showing performance 
across different numbers of features, boxplots_[variable_name]_FS.pdf shows 
performance across different feature selection methods, etc. 
 
Rdata: Directory contains ROC curves for each model run, e.g. M1_ROC.pdf is 
the ROC curve for model #1.  Directory also contains learning sets used within 
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CMA that specify what samples are in which cross validation folds.  These are 
only needed when doing nested cross validation. 
How to Run the CMA* Pipeline 
Copy the CMA* pipeline scripts to your own directory.  The CMA* pipeline scripts 
are located in: 
/protected/projects/pulmarray/biomarker_pipelines/CMA_pipeline/stable/scripts.  
Edit the user_parameters_template.pl to reflect the analysis you would like to 
run.  To run the CMA* pipeline, cd into the directory with the scripts you copied, 
including the user parameters file that you edited, and type:  
perl run_CMA_pipeline.pl  [your_user_parameters.pl].   
Here [your_user_parameters.pl] is the file with the parameters you specified by 
editing user_parameters_template.pl.  The Perl script will output the list of jobs 
being created and the location of the results directory. 
 
5.3.3 Example Output From CMA* Pipeline  
The CMA pipeline generates results files containing tables and visualizations that 
summarize the performance of each classifier chosen.  Toy data was used to 
generate the example output shown in this section.  The CMA pipeline generates 
separate files with the following content: classification performance (tables, ROC 
curves, and boxplots), selected features, and predictions and scores for each 
sample.  
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Classification performance, for all classifiers specified in the user parameters file, 
is written to a single output file, as shown by Table 17.  One row exists for each 
classifier, which is specified by a unique set of parameters, i.e. feature selection 
method (FS), number of features (NF) and inducer (INDUCER).  For each unique 
set of parameters, the cross validation accuracy, sensitivity, specificity, and AUC 
are shown (positive predictive value, negative predicted value, and average of 
sensitivity and specificity are recorded in the same output file  but are not shown 
here due to lack of space).  The features selected in cross validation and the 
number of times each feature is selected are written into a single file for each 
feature selection method specified in the user parameters file, as shown in Table 
18.   
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Table 17: CMA* Pipeline Report - Cross Validation Performance for Each 
Classifier 
FS NF INDUCER ACC SENS SPEC AUC 
wilcox.test_abs 2 class_oversampling_rf_JPG 0.94 0.958 0.923 0.948 
welch.test_eq_up_down 10 uncorrected_wv_JPG 0.94 0.958 0.923 0.915 
wilcox.test_abs 10 uncorrected_wv_JPG 0.94 0.958 0.923 0.913 
welch.test_eq_up_down 2 nbJPG 0.94 0.958 0.923 0.905 
 
Each row contains the performance statistics for a unique classifier, where a classifier is defined 
by the combination of, 1) feature selection method, 2) number of features, and 3) inducer.   
Abbreviations: FS = feature selection method, NF = number of features, CLASS = inducer 
(learning algorithm), ACC = accuracy, SENS = sensitivity, SPEC = specificity, wilcox.test_abs = 
feature selection of top n features by lowest Wilcoxon test P-value, welch.test_eq_up_down = 
feature selection of top n features by Welch t-test t-statistic where an equal number of features 
with the lowest and highest t-statistics are selected, class_oversampling_rf_JPG = random forest 
inducer that incorporates oversampling of the minority class, uncorrected_wv_JPG = weighted 
voting inducer, nbJPG = naïve Bayes inducer. 
 
 
Table 18: CMA* Pipeline Report - Selected Features With Cross Validation 
Frequency 
feature.ID times.selected 
feat_1 5 
feat_85 2 
feat_124 1 
feat_140 1 
feat_7 1 
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5.3.4 CMA* Pipeline Quickstart Guide 
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5.4 Discussion 
 
The CMA package was debugged and expanded to create CMA* and the CMA* 
pipeline was created to submit CMA* jobs to a cluster.  CMA* contains a critical 
bug-fix in CMA that was causing predictions to be assigned to the wrong 
samples.  The correct code was sent to the developer and will be included in the 
next version of CMA.  CMA* also includes additional classifiers (weighted voting, 
SVM RFE, top scoring pairs) and feature selection methods (linear models) that 
are useful for microarray biomarker development.  By parallelizing computation, 
the CMA* pipeline greatly speeds up biomarker development.  In addition, the 
pipeline generates tables and visualizations that are useful for comparing 
classification methods.  Finally, the CMA* pipeline enables ensemble biomarker 
development.  The pipeline enables creation of ensemble biomarkers that can be 
combined using simple combination rules like majority vote or put into a meta-
classifier (an ensemble method known as stacking).    
 
CMA* and the CMA* pipeline contain a combination of useful methods for 
biomarker development that were not previously available in a single software.  
This software is currently installed on a shared computing platform that serves 
the Boston University Medical Center.  The software is easy to implement by a 
user with minimal programming background and is well documented.  In 
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summary, CMA* and the CMA* pipeline will be useful tools for future biomarker 
development. 
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6. General Conclusions 
 
Building upon the previous work that identified a diagnostic bronchial mRNA 
biomarker for lung cancer, this work has expanded the scope of lung cancer 
biomarkers to include microRNA and gene expression in the bronchial and nasal 
epithelium, respectively.  This research has identified simple biomarkers that may 
lead to new clinical tests for lung cancer diagnosis and screening that are more 
accurate and less invasive. 
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